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Advisory Professors: Danielle A. Garsin, Ph.D. and Michael C. Lorenz, Ph.D.

The human microbiome is a diverse polymicrobial population comprised of both fungi
and bacteria. Perturbations of the normal microbiome can have a profound impact on health,
including the development of infections. Exploitation of these polymicrobial interactions has the
potential to provide novel treatment and prevention strategies for infectious diseases.
Enterococcus faecalis, a Gram-positive bacterium, and Candida albicans, a polymorphic
fungus, occupy overlapping niches as ubiquitous constituents of the gastrointestinal and oral
microbiome. Both species are also amongst the most important and problematic, opportunistic
nosocomial pathogens and are often co-isolated during infection. Surprisingly, these two
species antagonize each other’s virulence in both nematode infection and in vitro biofilm
growth.
Herein we identify the E. faecalis secreted bacteriocin, EntV, as both necessary and
sufficient for the reduction of C. albicans virulence and biofilms through the inhibition of hyphal
formation, a critical virulence trait of C. albicans. Furthermore, we demonstrate that the EntV
propeptide is proteolytically processed by the metaloprotease, GelE, in E. faecalis, resulting in
production of a highly active peptide of 68-amino acids, EntV68. The mature peptide effectively
blocks biofilm development in multiple media conditions and disrupts pre-formed biofilms,
which are resistant to current antifungal treatments. Moreover, EntV68 is efficacious against
clinical strains of C. albicans, including azole resistant strains. Biofilm development of other
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pathogenic Candida species is also impeded by EntV68 treatment, demonstrating the target
spectrum of EntV68 is not limited to C. albicans. EntV68 is protective in the murine macrophage
and oropharyngeal candidiasis (OPC) infection models at nanomolar concentrations. Epithelial
invasion, inflammation, and fungal burden in the OPC model were significantly reduced in
response to treatment with EntV68. Collectively, C. albicans cells present in the hyphal form
were greatly reduces in all models examined. Despite these profound effects, EntV68 has no
effect on C. albicans viability, even in the presence of significant host-mimicking stresses.
EntV68 associates with cell surface of both yeast and hyphal cells of C. albicans and deletion of
genes involved in hyphal morphogenesis and cell wall composition abrogate the inhibitory
activity in C. albicans biofilms. These findings demonstrate that EntV has potential as a novel
antifungal agent that targets virulence rather than viability.
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CHAPTER 1:

Background and Significance
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C. albicans as an Opportunistic Pathogen
Candida spp. rank 3rd among nosocomial pathogens, with C. albicans being the
prevalent species and there is a 30% rate of morbidly in device-associated infections in the
U.S. (1-4). There are two-main types of infections caused by C. albicans that differ very
drastically in severity: superficial infections of the mucosa, such as oral or vaginal candidiasis
and life-threatening systemic infections that occur when C. albicans enters the blood stream
and then infects organs throughout the body (5-7). C. albicans has specialized virulence and
fitness attributes that allow it to survive and adapt in diverse environments in the host (5). The
transition between yeast and hyphal morphotypes, expression of cell surface adhesins, and
biofilm development are among these adaptive traits that are also considered important
virulence factors (6).
As a commensal C. albicans can live in equilibrium with the normal bacterial flora on
mucosal surfaces (3, 4, 8). C. albicans is transmitted at birth from mother to infant and no
external environmental reservoirs exist, which suggests that C. albicans has coevolved with the
mammalian host (9) However, these commensal populations are frequently the source of
infection that arise from transmigration through the mucosal barrier or colonization of implant
devices (10). Several factors have been identified that influence the switch from commensalism
to pathogenesis in C. albicans such as: (1) changes in the normal microbial flora, (2) damaged
epithelial barriers, and (3) immune dysfunction (4, 8, 11). After the onset of C. albicans
superficial infections more severe systemic infections can occur (11-13). These blood-borne
disseminated infections often have considerable mortality rates, near 40%. Severe Candida
infections are most prevalent in immunocompromised individuals, such as those with HIV/AIDS
or being treated with immunosuppressive therapy (14-17). Healthy individuals with implanted
medical devices are also commonly plagued with Candida infections that stem from
colonization of the medical devices (18, 19).
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Clinical Importance of Biofilms
C. albicans has the ability to produce highly structured biofilms on abiotic and biotic
surfaces, which promotes the high morbidity and mortality correlated with device-associated
infections (20, 21). These highly structured biofilms are composed of different cell types that
form a striated pattern with round, budding yeast-form cells and/or oval pseudohyphal cells at
the bottom and elongated, cylindrical hyphal cells at the top encased in an extracellular matrix
(Fig. 1.1) (22-25). Of the bloodstream infections in the clinical setting 15% are caused by C.
albicans or closely related species; however, C. albicans is the predominant fungal species
found on medical devices (26-28). Different medical devices used throughout the body are
susceptible to C. albicans biofilm, such as mechanical heart valves, pacemakers, central
venous and urinary catheters, dentures and joint prosthetics to name a few (2, 29-31) .
Biofilms formed on medical devices have the potential to seed disseminated
bloodstream infections that can lead to systemic infections of tissue and organs. Astonishingly,
50% of the over five million central venous catheters placed annually in the U.S. become
infected with biofilms, both bacterial and fungal (2, 32). Routinely, once a medical device
becomes infected it is removed and the patient will undergo antimicrobial therapy. Since fungal
biofilms are resistant to traditional antifungal treatments, increased concentrations and longer
durations of antifungal treatment are required (33-37). However, in some cases removal of the
infected medical devices is costly or unsafe and the extremely elevated antifungal
concentrations used to treat the infection can lead to further complications such as kidney or
liver failure (15, 37, 38). Thus, due to the complicated nature of device-associated infections in
the U.S. alone, $6.5 billion is spent annually to treat these types of infections (39). Not only do
these infections have an immense economic impact, but also a significant health impact
resulting in an estimated 100,000 deaths per year (39).
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Figure 1.1: Stages of C. albicans biofilm development over time.
1) Adherence: yeast cell attach to an abiotic or biotic substrate. 2) Initiation: biofilm
development starts with cell-cell adhesion and hyphal morphogenesis. 3) Maturation: hyphal
cells form an extensive network encased in a secreted, extracellular matrix. 4) Dispersal: yeast
cells bud off the biofilm and disperse and adhere at new locations. Modified from: Finkel JS,
and Mitchell AP. Genetic control of Candida albicans biofilm development. Nature Reviews
Microbiology; 2010;9:109–18 (40-42). Permission to use this figure was granted by Copyright
Clearance Center (License #: 4242690280081).
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Role of Hyphal Morphogenesis During Biofilm Formation
Biofilm formation can be divided into four distinct stages composed of different
populations of yeast, psuedohyphal, and hyphal cells (Fig. 1.1) (23, 39, 40). C. albicans yeasthyphal transition is essential for maximum virulence potential and the biofilm growth cycle (13,
20, 21, 43). The early stages of biofilm formation are adherence and initiation, which consist of
yeast cell attachment to a substrate followed by development of psuedohyphae and then
hyphae. During maturation of the biofilms, cells are encased in an extracellular matrix, biomass
increases, and striated layers of yeast (bottom) and then hyphal cells (top) are observed. The
final stage of biofilm formation is dispersal where yeast cells bud off and disperse, allowing
them to form biofilms in other locations (Fig. 1.1) (23, 39, 40). The stages of biofilm growth are
interdependent with regulation of hyphal morphogenesis and controlled by a complex signaling
network.
Hyphal morphogenesis is regulated by intricate interconnected pathways in response to
environmental signals that induce or repress hyphal morphogenesis, giving rise to the distinct
morphologies that have been observed in C. albicans (13). Morphological variability allows C.
albicans to adapt to different environmental changes. Intriguingly, many of the distinct
morphologies can be observed during biofilm growth at distinct stages of development,
indicating differences in gene expression of biofilm cells in response to the biofilm
microenvironment. To form the striated biofilm structure described above cells must be able to
regulate hyphal morphogenesis (40, 42, 44, 45).
Three major signaling cascades have been identified to date that regulate hyphal
morphogenesis in C. albicans: (1) the cyclic AMP-protein kinase A pathway (cAMP-PKA), (2)
mitogen-activated protein kinase pathway (Cph1-MAPK), and (3) pH pathway (Rim101) (4648). The cAMP-pKA pathway is the central signaling pathway that responds to an array of
different conditions and regulates hyphal morphogenesis during biofilm growth via activation of
Ras1 (GTPase) by an unknown signal and receptor (49) (Fig. 2.1). Upon Ras1 activation,
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cAMP is synthesized from ATP by adenylyl cyclase (Cyr1) (50, 51). cAMP then activates PKA,
which consists of one of two redundant catalytic subunits, Tpk1 and Tpk2, and a regulatory
subunit, Bcy1. PKA then phosphorylates the downstream transcription factor, Efg1, which
regulates hyphal-specific genes (52, 53).
Efg1 is a key regulator of hyphal morphogenesis and has various functional roles in
both the repression and the induction of hyphal morphogenesis. This multi-functionality is owed
impart to the multiple functional domains of the protein (53). Efg1 is able to bind at least two
different DNA binding motifs (E-box and MCB). It interacts with the terminal transcription factors
of the other hyphal signaling cascades and modulates their functions. Post-translational
modifications are also thought to modulate the regulatory behavior of Efg1 (53, 54). Efg1 is one
of the core master regulators (Flo8, Rfx2, Gal4, Brg1, Bcr1, Rob1, Efg1, Ndt80, and Tec1) that
positively regulate biofilm development and form an intricately regulated transcriptional network
that controls biofilm-associated genes (Fig. 1.2) (23, 42, 55). Recently, an even larger set of
genes has been identified that encompasses this subset of core master regulators to include a
total of 51 transcription factors that regulate different aspects of biofilm development (56).
Additionally, other key transcriptional regulators of interest include the negative
regulators Nrg1 and Rfg1 that with co-repressor Tup1 negatively regulate hyphal-specific
genes and allow dispersal of yeast cells in the final stage of biofilm development (57). The
positive regulator of hyphal-specific genes, Ume6, is important for hyphal extension by
maintaining expression of hyphal-specific genes and is important for the later stages of biofilm
growth (54, 57, 58). Downstream from every hyphal morphogenesis signal cascade, Ume6 is
thought to be a global positive regulator of hyphal-specific genes and is negatively regulated by
Nrg1-Tup1 and to a lesser extent by Rfg1-Tup1 (59).
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Figure 1.2: C. albicans hyphal and biofilm development signaling cascade.

Ras1-cAMP-PKA (purple) is responsible for transducing the environmental signal to the
terminal transcription factor Efg1 (blue). Activated Efg1 is part of the biofilm core
regulators and positively regulates the biofilm transcriptional network (green), hyphal
specific and biofilm-associated genes. The positive regulator Ume6 regulates hyphal
elongation (brown) and is important for developing mature biofilms. Repressors Nrg1
and Rfg1 with the co-repressor Tup1 (red) negatively regulate the signaling cascade
and are important for the late biofilm stage, dispersal. Modified from Sudbery PE.
20

Growth of Candida albicans hyphae. Nature Reviews Microbiology; 2011;9:737-748 .
Permission to use this figure was granted by Copyright Clearance Center (License #:
4242730485058).
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Biofilm-Associated Genes
Nobile et al. (42) identified a subset of genes that are differentially regulated during
biofilm development. This subset of genes is regulated by different combinations of the sixbiofilm master regulators and includes cell wall proteins, metabolic proteins, and transporter
proteins. Functional analysis of these genes during biofilm growth revealed that cell wall
proteins play a direct role in biofilm development (42). Considering that the cell wall interacts
most directly with surface substrates and other cells it is no surprise that the cell wall and
surface proteins play a major role in biofilm formation. The cell wall of C. albicans is comprised
of primary carbohydrates and glycoproteins (8, 12). Chitin, β-1,3-glucan, and β-1,6-glucan
comprise the inner wall just above the cell membrane, while cell wall proteins and mannans
that are in the form of N- and O-linked glycosylation on the cell wall proteins constitute the
outer wall (Fig. 1.3) (8, 13). Adhesins directly mediate adherence to a substrate or other cells.
Several different adhesins have been identified in C. albicans by deletion of the gene resulting
in loss of adherence or due to homology to known adhesins (60). The content of the cell wall
and surface proteins can affect adhesin activity that results in masking or exposing adhesins to
the cell surface (8, 13, 60).
Two different classes of cell wall proteins have been identified in C. albicans: proteins
glycophosphatidylinositol (GPI) anchored to β-1,6-glucan and proteins with internal repeats
(Pir) linked to β-1,3-glucan (60). The GPI anchored cell wall proteins are the most abundant
and many are important for biofilm formation. One such protein is hyphal wall protein 1 (Hwp1),
a well-characterized GPI-anchored cell wall protein that is covalently linked to β-glucan.
Deletion of hwp1 reduces virulence in a mouse infection model and results in biofilm defects
(42, 55, 61, 62). The ALS (agglutinin like sequence, Als1-7, 9) family of proteins is a family of
GPI-anchored cell wall proteins, of which several have been identified as being important for
biofilm formation. Als1 and Als3 have both been shown to play important roles in hyphal
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Figure 1.3: The Candida albicans cell wall.
Two distinct layers make up the cell wall. The outer layer composed of O- and N-linked
mannans covalently linked to proteins to form glycoproteins. The inner layer is comprised of
polysaccharides β-1,3-glucan, and β-1,6-glucan and chitin. Modified from Gow NA, Hube B.
Importance of the Candida albicans cell wall during commensalism and infection. Current
Opinion in Microbiology; 2012;15:406–12 (13). Permission to use this figure was granted by
Copyright Clearance Center (License #: 4242731391290).
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morphogenesis and biofilm formation; deletion mutants have defects in biofilm growth (62, 63).
Over expression of the other ALS genes rescues the in vivo and in vitro biofilm growth defects
of an als1Δ/Δ als3Δ/Δ mutant, indicating redundancy in the function of the Als family of proteins
(62).
Both HWP1 and ALS1 are regulatory targets of BCR1 and over expression of either
rescues a bcr1 biofilm defect (42). However, overexpression of HWP1 does not rescue biofilm
growth defects of an als1Δ/Δ als3Δ/Δ mutant suggesting they have distinct roles during biofilm
formation (62). When biofilms of mixed mutant strains (als1Δ/Δ als3Δ/Δ and hwp1Δ/Δ) are
grown together the biofilm defects are overcome indicating Hwp1 and Als1/Als3 have
complementary functions (62). Heterologous expression of HWP1 in S. cerevisiae mediates
adherence to wild-type C. albicans but not the als1Δ/Δ als3Δ/Δ mutant (62). Taken together
these results suggest Hwp1 and Als1/Als3 have distinct complementary roles during biofilm
growth by mediating cell-cell attachment via interactions together on the cells surface.
Additional cell wall associated proteins have been shown to play important roles in
biofilm formation. Eap1 (enhanced adherence to polystyrene 1) is a GPI anchored protein with
a similar structure to the Als family and is important for biofilm initial adherence. Deletion of
eap1 causes a reduction in adherence to polystyrene and causes defects in both in vivo and in
vitro biofilm growth (64, 65). Rbt1 (repressed by Tup1) is also a GPI anchored protein that
belongs to the same family of adhesins as Hwp1 (60). Deletion of RBT1 results in mild biofilm
defects in vitro although additional deletions of HWP1 and HWP2 have enhanced biofilm
defects (66, 67). Expressed at high concentrations in C. albicans yeast cells, Ywp1 (yeast wall
protein 1) is an adhesin-like cell wall protein that is thought to act as an anti-adhesin by an
unknown mechanism (68, 69). Deletion of YWP1 results in loss of dispersal and increased
adherence suggesting that Ywp1 is important for dispersal, the final stage of biofilm
development (69). Most of the multiple families of adhesins are associated with hyphal growth
and play a major role in biofilm development. However, a balance of cell-substrate and cell-cell
adherence is important for biofilm integrity. Cabral et al. (70) found that overexpression of
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certain cell wall adhesins, such as PGA22, disrupted biofilm growth. Furthermore, upregulation
of cell adhesins had different consequences in mono-culture biofilms compared to
polymicrobial. Thus, regulation of cell ahesions is dependent on the nature of the biofilm and
substrate.
The secreted aspartyl proteases, (Sap1-10), are secreted proteases that are
differentially expressed in hyphal and yeast cells and important for adhesion, invasion and
tissue degradation during infection (11, 71). During biofilm formation the SAP-encoding genes
are significantly upregulated in both in vitro and in vivo growth conditions (42, 71). In denture
stomatitis, inflammation of the palatal mucosa in denture wearers is induced by biofilm growth
on the surface of the top of denture. Under these conditions, SAP8 expression is highly
unregulated followed by SAP5, 6, 2 and 1. Overall a positive correlation between proteinase
activity and biofilm formation associated with infection have been observed in C. albicans oral
isolates (71, 72). Bloodstream isolates of C. albicans have upregulated gene expression of
SAP5 and 9 during in vitro biofilm growth compare to isolates from other sites (73). Deletion of
SAP5 and 6 causes in vivo and in vitro biofilm defects (74).
The Saps have been shown to be hyphae-specific genes important for induction of
hyphae-infiltration (4, 75). However, the observations during biofilm growth suggest that the
Saps have functions distinct from hyphal invasion during infection (71-74). Defects in biofilm
adhesion suggest that these proteases are required for proper adhesion during the initiation
stage (74). Thus, the Saps may also play a role in both seeding new biofilm after dispersal and
maintaining adhesion during biofilm maturation (71, 73, 74). The dynamic expression of the
SAP genes over time suggests they play different roles during the stages of biofilm
development such as nutrient acquisition, cell-cell interactions (adhesion, quorum sensing),
and extracellular matrix production and remodeling (42, 71-74, 76).
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Antifungal treatment strategies
Traditional antifungal drug development is limited because humans and fungi are
evolutionarily closely related resulting in a limited number of probable drug targets and greater
potential for toxicity due to off target affects (77-79). Currently, three classes of traditional
antifungals (polyenes, azoles, echinocandins) are commonly used to treat C. albicans
infections (80). These antifungals have different advantages and limitations with toxicity and
cross reactivity being the main challenges (78).
Polyenes were the first antifungals discovered and are natural derivatives of antifungals
from Streptomyces spp. (77, 81). Polyenes generate pores in the cell membrane by binding
ergosterol, leading to ion leakage and ultimately cell death (82, 83). The most successful
polyene is Amphotericin B and is commonly used for serious fungal infections, but has severe
toxic side affects (77, 84). Azoles disrupt the cell membrane fluidity by disrupting biosynthesis
of ergosterol and are extensively used because of their low toxicity (85). Fluconazole,
itraconazole, voriconazole, and posaconazole are the most commonly used azoles and are
often used as a first measure against fungal infections (77). Azole resistance has increased
with the widespread use of azoles in the clinical setting (83). Echinocandins are the newest
class of antifungal and inhibit cell wall biosynthesis by inhibiting β-1,3-glucan synthase (Fks1)
(86). Caspofungin, anidulafungin, and micafungin are the most commonly used echinocandidns
and have little to no side effects (87).

Antifungal Resistance in C. albicans Biofilms
The ability of C. albicans to form biofilms influences antifungal drug resistance due, in
part, to the inability to disrupt or permeabilize the biofilms (88, 89). The inability to disrupt C.
albicans biofilms correlates with the hypha-yeast ratio, where biofilms with more than 50%
hyphae have a significant increase in compression strength thus increasing resistance to
disruption (90). Therefore, the structure of the biofilm allows C. albicans to persist even in the
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presence of antifungals (20, 21, 88). Biofilms of C. albicans are up to 1,000-fold more resistant
to antifungals compared to planktonic cells (20, 88, 91, 92).
One key characteristic of biofilm growth is the encasement of the biofilm in the
protective extracellular matrix that protects the biofilm integrity and acts as a physical barrier
against antifungal agents. The extracellular matrix of C. albicans biofilms is comprised of
proteins, polysaccharides, lipids, and nucleic acid. Although each of the extracellular matrix
components augment the architecture and integrity of the biofilm, only polysaccharides and
nucleic acid have been shown to enhance antifungal resistance (93-97).
The extracellular matrix also contains polysaccharides, mostly mannan-glucan
complexes (98). The β-1,3-glucan synthase gene, FKS1, produces cell wall β-1,3-glucan that is
deposited into the ECM of C. albicans biofilms. Nett et al. (20, 99) demonstrated that β-1,3glucan sequesters antifungals, impeding diffusion of the antifungal and conferring resistance of
the biofilm to antifungals. Heterozygous deletion of FKS1 (GSC1) reduced β-1,3-glucan
synthesis and deposition in the extracellular matrix, which increased biofilm susceptibility to
fluconazole (99). Moreover, depletion of β-1,3-glucan by β-1,3-glucanase treatment increased
sensitivity to fluconazole. Whereas, addition of exogenous β-1,3-glucans increases resistance
to fluconazole in planktonic cells (20).
Another component of the extracellular matrix that contributes to antifungal resistance is
extracellular DNA (eDNA). DNase treatment enhances caspofungin and amphotericin B
disruptive activity of mature biofilms (100). eDNA contributes to the maintenance and stability
of biofilms and is not required for the early biofilm stages (adherence and initiation). DNase
treatment of mature biofilms disrupts biofilm integrity, but does not affect establishment of
biofilm (101). Moreover, addition of eDNA to biofilms increases biofilm biomass and does not
affect adherence (101). eDNA is also present, to a lesser extent, in the supernatant of
planktonic cells and can be enhanced by addition of chitinase in both planktonic and biofilm
cells suggesting that the eDNA source is from cell lysis (97, 100, 101).
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Efflux pumps also contribute to the intrinsic resistance of C. albicans biofilms. There are
two major classes of efflux pumps in C. albicans: ATP-binding cassette transporters (CDR1
and CDR2) and major facilitator class pumps (MDR1) (80, 102, 103). In the presence of
antifungal drugs these efflux pumps are upregulated in planktonic cells (80, 102). However,
during biofilm growth these efflux pumps are upregulated in response to surface adherence,
which further influences resistance to antifungal agents (42, 104, 105). Independent of efflux
pumps, persister cells contribute to antifungal resistance in biofilms (88). Biofilms are
metabolically heterogeneous, with cells at the base more dormant than those at the surface.
Persister cells are metabolically dormant yeast cells found in biofilms of C. albicans that are
exceedingly resistant to antifungals and can survive very high concentrations of antifungal
drugs to seed new biofilms once antifungal treatment ceases (88, 106). Most antifungal are
fungistatic and not fungicidal and are more effective against actively growing cells, which
explains the resistance observed in persister cells.
Due to the rise in antifungal resistance the discovery of novel antimicrobial agents is
imperative. The rise in resistance to traditional antimicrobials is due impart to targeting
essential processes that increase the selective pressure for mutations that confer resistance (3,
91, 92). One promising alternative is the use of antimicrobials that target virulence factors, such
as hyphal morphogenesis and the biofilm matrix in C. albicans (3, 4, 92). Although immense
advances have been made recently in understanding the molecular details of hyphal
morphogenesis and biofilm formation, clinical application of virulence targeting therapeutics has
remained underexplored.

Bacterial and C. albicans Interactions and Health Related Prevalence
In the host C. albicans encounters hostile environments with antagonism from the host
and commensal bacterial flora. As a result C. albicans has developed a multitude of strategies
to overcome these challenges, making C. albicans a resilient pathogen (107). However, in a
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healthy host C. albicans is for the most part benign. Although the switch from commensal to
pathogen is largely dependent on the status of the host, the microflora and presence of other
pathogens also play a role in this switch. As both a commensal and pathogen of the human
host C. albicans encounters numerous bacterial species, which include both pathogenic and
commensal species (11, 108-111).

Complex interactions have been previously documented

that include both synergistic and antagonist interactions where bacteria and C. albicans can
have direct or indirect interactions (108, 110). These interactions can influence the growth and
physiology of both microbes, often modulating the virulence of C. albicans (108, 112, 113).
Physical interactions where bacteria adhere to C. albicans has been demonstrated with specific
affinity for hyphal cell wall adhesins (112-114). Chemical exchange between C. albicans and
bacteria that involves crosstalk between quorum sensing molecules has also been
demonstrated in previous studies (114, 115).
Apart from the studies described here, there are only three bacterial species whose
interactions with C. albicans have been significantly characterized, Pseudomonas aeruginosa,
Staphylococcus aureus, and Streptococcus gordonii. As the complexity of these types of
interactions are being uncovered, two main types of interactions have been observed:
antagonism between pathogens (P. aeruginosa−C. albicans) and synergism between
pathogens (S. aureus−C. albicans, S. gordonii−C. albicans) (110, 113, 116).
Antagonistic Interactions
Antagonistic interactions between P. aeruginosa and C. albicans have been the most
extensively examined and reveal a complex dynamic between two pathogens that are
commonly co-isolated from the lungs of cystic fibrosis (CF) patients (117-119). A Gramnegative bacterium, P. aeruginosa is an opportunistic pathogen with a multitude of virulence
factors (120). In clinical cases where C. albicans is found during pulmonary infection, such as
pneumonia and cystic fibrosis-related infections, it is usually co-isolated with bacteria (121,
122). Furthermore, C. albicans and P. aeruginosa are commonly co-isolated from burn wounds.
Burn victims often have primary infections of P. aeruginosa that are followed by severe life-
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threatening candidemia (108). Similarly, increased virulence was observed in a murine
pseudomonal burn wound infection model during co-infection with P. aeruginosa (123). In vitro
investigations in rats found that pre-colonization with C. albicans in lung tissue increased rates
of P. aeruginosa associated pneumonia (122). This suggests that C. albicans mucosal biofilms
promotes secondary bacterial infections, which has also been supported by a clinical study of
ventilator patients who had an increased rate of bacterial infection with prior C. albicans
colonization (124).
Conversely, in vitro examination of C. albicans and P. aeruginosa demonstrated
antagonistic interaction in a wide range of environmental conditions. During biofilm growth P.
aeruginosa preferentially adheres to C. albicans hyphal cell and forms biofilms on the hyphae,
which leads to killing of C. albicans. This hyphal specific killing is due to the production of
pseudomonal virulence factors, secreted haemolytic phospholipase and phenazines (125-127).
Furthermore, P. aeruginosa inhibits the yeast-hyphal transition by production of a 3-oxo-C12
homoserine lactone, a bacterial quorum sensing signaling molecule that mimics farnesol (126,
128). Farnesol is a quorum sensing signal molecule produced by C. albicans, which represses
hyphal morphogenesis and plays an important role during biofilm dispersal (40, 129). Farnesol
and 3-oxo-C12 homoserine lactone inactivate the Ras1-cAMP-PKA pathway and increase
TUP1 expression, thus blocking expression of hyphal-specific and biofilm genes that are
positively regulated by Efg1 (129-133). Homoserine lactones and similar compounds are
produced by other Gram-positive bacteria that similarly repress hyphal morphogenesis in C.
albicans, suggesting cross-talk between bacteria and C. albicans might be important in
polymicrobial interactions (134, 135).
In addition to the effects P. aeruginosa has on C. albicans, C. albicans does exert
changes in P. aeruginosa. Farnesol inhibits the Pseudomonas quinolone signal (PQS), which
responds to the production of 3-oxo-C12 homoserine lactone in P. aeruginosa and controls the
production of phenezine products (136). During co-culture of P. aeruginosa and C. albicans, a
reduction in PQS and thus phenezine products, suggests that the production of farnesol from
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C. albicans is great enough to have an influence on P. aeruginosa (136). Taken together these
results suggest an antagonistic relationship exists. However, these pathogens are frequently
found during co-isolation in the clinical setting suggesting that a synergistic relationship might
exist in certain settings. It is possible that the antagonistic behaviors observed in vitro allow P.
aeruginosa to use C. albicans biofilms as a sort of scaffold or foundation, thus increasing the
survival and colonization rates. There is apparent antagonism in vitro, but synergism in vivo,
similar to our observation with E. faecalis and C. albicans.
Antagonist interactions between C. albicans and Streptococcus mutans have also been
documented. S. mutans are Gram-positive bacteria found in the oral cavity and are associated
with dental caries. They are resistant to highly acidic environments and produce acids that are
associated with dissolution of the tooth surface, which leads to dental caries (137, 138). S.
mutans and C. albicans are commonly co-isolated from early childhood dental caries and
denture plaques of healthy individuals (139, 140). Similar to P. aeruginosa, S. mutans produces
quorum sensing signaling molecules that inhibit C. albicans hyphae development.
The competence-stimulating peptide (CSP) was found to inhibit hyphal development in
C. albicans (141). CSP is necessary for natural competence of S. mutans. Additionally, trans-2decenoic acid, a diffusible signaling molecule inhibits hyphal development of C. albicans (142).
SigX, an alternative sigma factor in S. mutans, is the master regulator of quorum sensing (143).
Strong induction of sigX is observed in S. mutans biofilms grown with C. albicans compared to
monoculture biofilms suggesting that C. albicans stimulates quorum sensing signaling in S.
mutans (144).
Synergistic Interactions
Adhesion is an important factor for C. albicans colonization, pathogenesis and
polymicrobial interactions. The ALS proteins in particular play an important role in the biofilm
lifecycle and polymicrobial interactions. Many of the clinical conditions where C. albicans is coisolated with bacteria are considered biofilm-associated and adherence and/or colonization to a
surface are a requirement for infection (145). The ALS (agglutinin-like sequence) genes encode
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eight different glycoproteins that contain an N-terminal domain with adhesive function that are
found diffusely over the cell surface of C. albicans (146).
A vital component in inter-kingdom interactions, coaggregation is essential for
polymicrobial communities found in the oral cavity and facilitates the complex architecture
found in dental plaques. C. albicans is capable of adhering to various oral streptococcus
species (S. mutans, S. salivarius and S. gordonii). The ALS proteins mediate these interactions
with streptococci during polymicrobial biofilm development. Specifically, Als3 in C. albicans is
necessary for biofilm formation with S. gordonii on a salivary pellicle (147). Furthermore, S.
gordonii was able to bind Saccharomyces cerevisiae heterologously expressing C. albicans
Als3p (147). Als1 was also found to bind to the surface of S. gordonii; the Als proteins have
similar structures, and thus redundant function is feasible. The presence of S. gordonii
enhanced hyphal morphogenesis and biofilm formation in human saliva mediated by SspA and
SspB bacterial surface proteins that interact with Als1 and Als3 (146, 148). Additionally,
quorum sensing signaling via luxS regulation of autoinducer-2 (A-II) is necessary for enhanced
hyphal morphogenesis and biofilm formation (149).
Synergistic interactions between Staphylococcus aureus and C. albicans have been
observed. S. aureus has an affinity for binding to hyphal cells of C. albicans that is mediated by
Als3 on the surface of C. albicans (113). S. aureus, a Gram-positive opportunistic pathogen
found commonly on the skin, possesses a series of virulence factors that contribute to its
significant prevalence in nosocomial infections in immunocompromised individuals (150). S.
aureus was unable to bind to the adhesin-deficient mutant strains of C. albicans ALS3 (113). In
addition, S. aureus was able to bind the recombinant purified N-terminal domain of Als3 and
Saccharomyces cerevisiae heterologously expressing C. albicans Als3p (113). In an ex vivo
murine co-infection model, tongues excised from mice where inoculated with C. albicans and S.
aureus in a 12-well plate, S. aureus was found in the outer layers of the tissue when tongues
were infected with S. aureus only or with the ALS3 mutant strain. Conversely, tongues infected
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with S. aureus and wild-type C. albicans had S. aureus in epithelial tissue with invasive hyphae
(113).
The interactions between C. albicans and S. aureus have also been examined
extensively in multiple animal models that demonstrate a significant increase in virulence of
both microorganisms. During intraperitoneal infections of mice with C. albicans and S. aureus,
mice have increased mortality rates and both microorganisms are found together in the spleen,
pancreas, and esophagus. This demonstrates synergistic behavior during dissemination from
the intraperitoneal site of infection, similar to in vitro observations (151-153). Co-infection with
C. albicans and S. aureus in a peritonitis murine model significantly increased mortality
compared to mono-infection and increased fungal and bacterial burden was observed during
co-infection. Increased proinflammatory cytokines (IL-6 and G-CSF) and neutrophil infiltration
was observed during co-infection. Treatment with nonsteroidal anti-inflammatory drugs
(NSAIDs) increased mouse survival and lowered fungal and bacterial burdens in the kidneys
and spleen (154).
C. albicans has complex interactions with both pathogens and commensal bacteria
found in the human host in various niches. These complex interactions can be physical
interactions where bacteria adhere with specific affinity to hyphal cells, as has been
demonstrated to occur with C. albicans hyphal cell wall ahesions (112, 113). Chemical
exchange between C. albicans and bacteria that involves crosstalk between quorum sensing
molecules has also been observed (133, 155). Furthermore, a combination of these types of
interactions can transpire between C. albicans and bacterial species, alluding to the complexity
of the inter-kingdom interactions that occur.

Co-isolation of C. albicans and E. faecalis
The most well studied niches of C. albicans are the gastrointestinal (GI) and urogenital
tracts and it is well documented to come into contact with the bacterial flora, such as
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Enterococcus faecalis. Interestingly, co-isolation of C. albicans and E. faecalis is common, of
which the frequency is likely due to their biological similarities, specifically colonization of
overlapping niches (156-158). Both are opportunistic pathogens causing serious infection in the
presence of immunological dysfunction.
The prevalence of C. albicans and E. faecalis co-isolation from sites throughout the
human host is effectively demonstrated by a large-scale retrospective examination of 67,765
different clinical samples (109). The samples were collected at a large teaching hospital in
Germany over a two-year period. Candida spp. were detectable in about 7.7% of the samples
that included blood, CSF, feces, sputum and skin. The frequency of E. faecalis isolation
increased 2-fold in the Candida-positive samples compared to Candida-negative samples. This
trend was further increased in Candida-positive samples from blood and ICU patients,
demonstrating the prominence of co-infection in more severe infections and individuals with
pre-existing medical conditions (109).
Commonly co-isolated from the oral cavity of individuals with secondary root canal
infections, C. albicans and E. faecalis are typically resistant to antimicrobials, a probable cause
for failed root canal treatment strategies (159). During root canal treatment, the infected root
canals are mechanically removed and irritants are chemically removed followed by blocking the
root canal system with dental filling (gold, porcelain, silver amalgam, polymethyl methacrylate
resin, PMMA) to eliminate microbial activity thus preventing reinfection. However, absolute
removal of all microorganisms from the root canal is not always achieved and the oral cavity is
abundant with microorganisms that can colonize microspaces between the dental filling acrylic
and tooth surface (160-162).
Multifaceted microbial communities that consist of anaerobic bacteria (strict and
facultative) and fungi reside in the root canals of infected teeth (163, 164). Of these microbes,
E. faecalis and C. albicans are equipped to resist various endodontic treatment strategies that
allow them to survive and cause secondary root canal infections. (165-167).
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Many studies demonstrate the importance of C. albicans and E. faecalis separately
during secondary root canal infection. Yet, only a handful of studies investigate the co-isolation
of these microorganisms. Given their pathological similarities during periodontal infections it is
plausible that the occurrence of co-infection rates is underrepresented. A study investigating
single-rooted teeth with pulp necrosis, found that samples collected after root canal treatment
had increased populations of enterococci co-isolated with Candida spp. and/or enteric bacteria
(168). However, the majority of samples tested had enterococci mono-infections, suggesting
that interactions with other microorganisms are not necessary for this type of periodontal
infection (168).
Although secondary root canal infections are treatable with additional surgical removal
and debridement of the infected root canal and filling, if left untreated can become a more
severe systemic infection. C. albicans and E. faecalis that survive the root canal system can
spread to the periodontal tissues and invade the bloodstream, which can lead to bloodstream
infections (BSI) and followed by development of endocarditis. BSIs with at least two different
microorganisms are considered polymicrobial BSI and are on the rise with rates ranging from
5% to 32% of all BSI reports (169-172). With increased mortality rates (21%-63%) compared to
mono-microbial mortality rates, polymicrobial BSIs are a growing concern (169, 170).
Of more than 8000 reported incidences of candidemia (from 1965 to 2007) 23% were
polymicrobial, suggesting that high rates of polymicrobial BSI occur with candidemia (157). An
extensive study examining patients with candidemia found that of 372 patients, 141 patients
from 8 Veterans Affairs hospitals and 231 patients from a tertiary care hospital, 27% had
polymicrobial BSI (24% with synchronous bacteremia and 3% with more than one Candida
spp.) (157). Of the patients with synchronous bacteremia (88 patients) 27% where infected with
Enterococcus spp. Furthermore, the most frequent source of polymicrobial BSI is from intraabdominal infections that are frequently the result of loss of GI integrity allowing
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microorganisms, such as C. albicans and E. faecalis, from the GI tract to infect the peritoneal
cavity (170, 173-175).
Most populations of C. albicans and E. faecalis are located in the GI tract where they
act as commensals and are for the most part benign. However, if the host becomes
immunocompromised these microbes can become pathogenic and the populations in the GI
tract are a common reservoir for more severe types of infections. Intra-abdominal infections
(IAI) are commonly caused by infection from the GI tract microbiota and include many
pathological conditions that can range from uncomplicated, where only one organ is infected
and the infection does not progress to the peritoneum, to complicated, where the infection
progresses past the organ to the peritoneum causing localized or diffuse peritonitis (176,
177).
Peritonitis is further classified into primary, secondary or tertiary peritonitis (176).
Primary peritonitis is a disseminated infection with no loss of GI tract integrity and mainly
occurs in pediatric patients. The most common form, secondary peritonitis is an acute
peritoneal infection that results from loss of GI integrity due to perforation of the GI tract or from
intra-abdominal viscera from infected organs (e.g. gangrenous appendicitis). Recurrent
infections of the peritoneal cavity that follow primary or secondary peritonitis are classified as
tertiary infections. These types of infections can be acquired from the community or healthcare
setting. The latter is associated with increased mortality due to the status of the host and multi
drug resistance of the infections (178). Additionally, increased mortality rates (~%30) are
associated with severe sepsis or toxic shock in secondary infections (179-181).
A retrospective study of 163 adult patients with intra-abdominal candidiasis (IAC)
compared to 161 patients with candidemia found increased rates of bacterial co-infections in
patients with IAC (67%) compared to polymicrobial BSI (6%) (182). Different types of IAC were
evaluated: intra-abdominal abscesses (55%), secondary peritonitis (33%), primary peritonitis
(5%), infected pancreatic necrosis (5%), and cholecystitis/cholangitis (3%). The most common
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Candida spp. isolated were C. albicans (56%) and C. glabrata (24%). Consistent with previous
studies, enteric pathogens (Enterococcus and Enterobacteriaceae) were co-isolated with
Candida spp (183, 184). Of the 110 patients with bacterial co-infection, enterococci were most
abundant (29%), followed by Escherichia coli (19%) and Klebsiella spp. (15%) (182). However,
the mortality rates for IAC mono-infection and IAC bacterial co-infections are comparable in
these investigations, suggesting that Candida spp. are capable pathogens and not significantly
modulated by co-infecting bacteria in IAI (182, 185).

E. faecalis Pathogenesis
Enterococci are the initial colonizers of the GI tract in infants and were once only
considered as commensal colonizers with nominal clinical relevance. However, over the last
four decades, with increased use of antibiotics, enterococci have become prominent
opportunistic pathogens responsible for causing numerous types of infections: urinary tract
infections (UTI), IAI, bacteremia, and endocarditis (186). Antibiotic resistance is directly related
to the emergence of enterococci as a clinically important pathogen and the most clinically
significant species are Enterococcus faecalis and Enterococcus faecium (186, 187). Since
enterococci are intrinsically resistant to many antibiotics, have the ability to acquire resistance
genes, and are tolerant to antibiotics that target the cell wall, treatment of enterococcal
infections is often problematic (187, 188). Thus, the use of combinational therapy is required to
synergistically acquire bactericidal effects (189).
As part of the microflora enterococci colonize the GI tract of mammals (including
humans) and insects. Although both E. faecalis and E. faecium colonize humans, E. faecalis
colonizes the GI tract at a higher density (107 CFU/μg) than E. faecium [191]. E. faecalis is also
the predominant species of enterococci found in the urogenital tract. The endogenous
microflora was previously thought to be the predominant source of enterococcal infections.
Nevertheless with increased investigations in the clinical setting, transmission of pathogenic
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enterococci from nosocomial sources (e.g. hands of healthcare provider) has been extensively
documented (190, 191). The ability of enterococci to persist for extended periods on hands (60
minutes) and inanimate objects (4 months) creates a reservoir for continual transmission in the
hospital setting (192). Necessary for the numerous types of infections they cause, E. faecalis
has a multitude of virulence factors, such as: cytolysin, gelatinase, serine protease,
aggregation substances, Esp (enterococcal surface protein), Ace (adhesin to collagen of E.
faecalis), EfaA (E. faecalis antigen A), EbpABC (endocarditis and biofilm-associated pili), and
enterococcal capsule (193). Acquisition of extrachromosomal elements plays an important role
in adaptation and survival of enterococci (194). Extrachromosomal elements are usually
acquired by conjugation, where conjugative plasmids are transferred from a donor to recipient
controlled by peptide sex pheromones (194). Antibiotic resistance, elevated resistance to UV
light, virulence factors and bacteriocins are frequently plasmid-determined traits. Thus,
significant genetic diversity in response to environmental selection pressure is observed in
enterococci (195, 196).
Part of the core genome, the proteases, gelatinase (GelE, a matrix metalloprotease)
and a serine protease (SprE), in E. faecalis are important for degradation and damage of host
tissues during infection (197). These proteases affect a broad range of host functions by
degradation of host connective tissues and proteins, and interference with host cell signaling
and immune response (198, 199). Included in a single operon, GelE and SprE gene expression
is regulated by the fsr (E. faecalis regulator) genes that encode a canonical two-component
system, a homolog to the agr (accessory gene regulator) operon in S. aureus (200, 201).
The response regulator (FsrA) positively regulates the fsr genes (fsrABCD) and
downstream virulence factors (gelE, sprE). A quorum sensing two-component system, Fsr
responds to increased concentrations of a peptide pheromone encoded by fsrD, gelatinase
biosynthesis-activating pheromone (GBAP) that is secreted and processed by the
transmembrane protein FsrB. FsrA is constitutively expressed at basal levels, when threshold
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concentrations of extracellular GABP have accumulated the histidine kinase, FsrC is
phosphorylated followed by phosphorylation of the response regulator, FsrA. This signal
transduction via the Fsr system results in upregulated expression of the fsr genes and
downstream virulence factors, gelE, sprE (197, 202).
Although both GelE and SprE, to a lesser extent, are important virulence factors, only
GelE activity and role in virulence has been extensively examined. The gelE gene encodes a
509-amino acid protein of which 29-amino acids at the N-terminus serve as a Sec secretion
signal sequence. This signal sequence is cleaved upon secretion resulting in release of the
proenzyme of 480-amino acids. After secretion the proenzyme is further proteolytically
processed at the N-terminus and C-terminus by an autocatalytic process resulting in the mature
protein of 33kDa (203, 204).
GelE is a member of the M4 family of proteases and is similar to thermolysin from
Bacillus thermoproteolyticus and aureolysin from Staphylococcus aureus (205, 206). With
broad substrate specificity, GelE has the ability to hydrolyze gelatin, cleave enterococcal
conjugative sex pheromones, and has several host-derived substrates important during
infection (insulin B chain, endothelin, hemoglobin, fibrinogen, fibronectin, collagen, and laminin)
(207, 208). Furthermore, GelE interferes with the innate immune response by inactivating
human antimicrobial peptides LL-37 and β-defensins and is pertinent for E. faecalis
dissemination (209-211).
A serine glutamyl endopeptidase of 25kDa in size, SprE is similar to staphylococcal
glutamyl endopeptidases V8 and GluSE (212, 213). Similar to GelE, insulin, fibrinogen, and
casein have been observed as substrates of SprE and disruption of sprE results in decreased
virulence in different infection models, mouse peritonitis, Caenorhabditis elegans, and a rabbit
endophthalmitis (201, 214-217). SprE enzymatic activity is modified in the presence of GelE
similar to reports in S. aureus, where the GelE homolog, aureolysin, inhibits autocatalytic
processing of the SprE homolog, SspA (V8), by proteolytically processing the N-terminus of
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SspA by aureolysin (218, 219). Purification of SprE proenzyme from gelE mutant supernatant
resulted in purification of several forms of SprE that were proteolytically processed at both the
N-terminus and C-terminus (218, 220). Three different mature forms of SprE were purified that
had enzymatic activity (Leu1-Ala237, Ser-1-Glu227, Leu1-Glu227). However, only one form of SprE
(25kDa) was purified from wild-type supernatant (218, 220). Although GelE processes SprE,
the reverse is not apparent because a sprE insertion mutant produces gelatinase (201).
Considering the interconnected gene regulation and proteolytic processing of GelE and
SprE, it no surprise that they function in combination. While GelE and SprE play independent
roles in different infection models (mouse peritonitis, Caenorhabditis elegans, rabbit
endophthalmitis) disruption of both proteases had an additive effect (201, 214-217). Moreover,
roles for both GelE and SprE have been observed in biofilm development and regulating
autolysis in E. faecalis (221). Deletion of gelE resulted in a significant reduction in biofilm
biomass compared to wild-type biofilms. Whereas deletion of sprE resulted in accelerated
biofilm development and increased autolysis, suggesting that interplay between these
proteases controls biofilm development in E. faecalis (221).

E. faecalis Commensalism
Enterococci colonize the GI tracts of mammals, reptiles, birds and insects, which
suggests that enterococci have been part of the GI microflora since the early Devonian period,
(~412 MYA), making them one of the earliest colonizers of the GI tract (222-224). In the human
GI tract, enterococci are predominantly located in the small and large intestine (jejunal, ileal,
cecal, and recto-sigmoidal sections) (225). E. faecalis and E. faecium are the predominant
enterococci found in human feces, and E. faecalis is most common species found in the GI
tracts of mammals and insects (226, 227).
E. faecalis is a member of the lactic acid group of bacteria (LAB), which are low-GC
gram-positive bacteria that produce lactic acid as a major end product of carbohydrate
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fermentation [232,233]. Many of the LAB are used as probiotics, specifically Lactobacilli spp.,
which have been shown to benefit GI health (228, 229). In spite of the fact that enterococci are
as abundant in the human GI tract as lactobacilli, they are commonly associated with being a
multidrug resistant (MDR) pathogen (228). Although commensal enterococci can act as
opportunistic pathogens by translocating across the mucosal barrier causing systemic
infections in immune-compromised individuals, more commonly infections stem from
colonization, overgrowth, and translocation of hospital-adapted strains that have enhanced
pathogenicity and antibiotic-resistance (230, 231).
Enterococci are commonly used in food fermentation and preservation, traditionally
used in cheeses, fermented meats and vegetables manufactured in Mediterranean countries
(232-234). E. faecium and E. faecalis are the most commonly used and impact the ripening and
aroma development in these food products (229, 233). Enterococci are not purposely added as
starter cultures to these types of food. However, they occur in high numbers and their natural
habitat is probably not fermented food, but an outside environmental source that has yet to be
identified (235).
Enterococci as probiotics are used in countries (European Union) other than the US
(229, 236, 237). E. faecium and E. faecalis are the species most commonly used as probiotics.
The E. faecium strain SF68 probiotic, was demonstrated to be clinically effective in children for
treatment of diarrhea and prevention of diarrhea due to antibiotic treatment (238). The efficacy
of E. faecium SF68 in treatment of intestinal infections is likely due to the strain being part of
the natural intestinal microflora and having a short doubling time in optimal conditions. Growth
inhibition of E. coli, Salmonella serovars, Shigella spp. and Enterobacter spp by E. faecium
SF68 was demonstrated in vitro and shown to tolerate the extreme conditions of the GI tract
(239). Other probiotic preparations containing E. faecium have been shown to reduce irritable
bowel syndrome, dysbiosis as a result of foodborne pathogens, and lowering of serum
cholesterol (240, 241).
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Bacteriocins Produced by Gram-positive Bacteria
Bacteriocins are produced by Gram-positive and Gram-negative bacteria and are
ribosomally synthesized proteinaceous secreted compounds that have antimicrobial activity
against other bacteria, typically those that are closely related to the bacteriocin producing
species. Production of bacteriocins in Gram-positive bacteria, especially the lactic acid bacteria
(LAB), has been increasingly studied with the growing interest of probiotic LAB. Bacteriocins
produced by Gram-positive bacteria can be organized into four major groups: (1) lantibiotics,
(2) small non-modified peptides, (3) large proteins, and (4) cyclic peptides. The classification of
bacteriocins from Gram-positive bacteria is continually modified with the discovery of new types
of bacteriocins. However, Heng et. al. (242) have formulated a systematic classification plan
based on previous literature that encompasses recently characterized bacteriocins (243-245).
Class I bacteriocins are the lantibiotic bacteriocins that contain modified amino acids
that are not genetically encoded

(246). Lantibiotics are produced ribosomally as precursor

peptides that undergo post-translational modifications to produce the non-genetically encoded
amino acids lanthionine (Lan), 3-methyllanthionine (MeLan), dehydroalanine (Dha), and
dehydrobutyrine (Dhb) (247). Class II bacteriocins are small (<10 kDa), unmodified (nonlantibiotic and non-cyclic) peptides that encompass bacteriocins from diverse origins making it
the largest class of characterized bacteriocins (248). Although most characterized bacteriocins
from Gram-positive bacteria are small (<10 kDa), class III contains larger (>10 kDa)
bacteriocins that are typically heat liable, but not always (243, 249). The most distinctive
bacteriocins produced by Gram-positive are the cyclic bacteriocins of class IV, which are posttranslationally modified to produce the mature cyclic peptide (250).

Bacteriocin Production in E. faecalis
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Enterococci that produce bacteriocins have been isolated form a wide-range of
environments. Bacteriocin-producing enterococci are commonly found in cheeses, fermented
vegetables and meats, thus, have been implicated in food preservation (229, 233, 250). The
high frequency of bacteriocin-producing enterococci isolated from healthy individuals stool
samples suggests that they are important part of the healthy microflora and may benefit the
host and microbe (251). Although bacteriocin production in LAB is commonly associated with
probiotics and benefiting the health of the GI tract, enterococcal bacteriocins have also been
associated with infection (252, 253).
In E. faecalis bacteriocin encoding genes are often carried on mobile genetic elements,
such as conjugative plasmids, suggesting that efficient dissemination of bacteriocin-producing
traits may be important for survival and virulence. Cytolysin is a secreted lantibiotic class of
bacteriocins with cytotoxic effects on prokaryotic and eukaryotic cells (252, 253).
Epidemiological data support a role for the cytolysin as a toxin in human infection. Enrichment
for cytolysin expressing E. faecalis has been observed in the hospital-acquired populations
compared to community acquired populations of isolates derived from infection (254). These
findings suggest that selection pressure for cytolysin activity is prevalent in the hospital
environment, which corresponds to experimental and clinical evidence that cytolysin activity
plays an important role during infection (255).
On the other hand, the heat-stable circular bacteriocin AS-48 produced by E. faecalis
strains that are commonly isolated from cheese, milk, and fermented food products has
potential as food biopreservative (250, 256). This bacteriocin is encoded on a plasmid that
contains ten biosynthetic genes (257). Arranged into five alpha helices giving it a compact
globular structure, this 70 amino acids bacteriocin is circularized head to tail by a peptide bond.
AS-48 has broad inhibitory spectrum that includes both Gram-positive and Gram-negative
species (250). AS-48 is active against foodborne pathogens, toxigenic bacteria and bacteria
associated with food spoilage (258).
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The role of bacteriocins production in natural environments is debatable. However, one
logical and common idea is that bacteriocins provide the producing organism with a fitness
benefit that allows them an ecological advantage over competitors (259). The occurrence of
bacteriocins as a beneficial probiotic trait in the human GI tract and as a virulence trait during
infection, suggests that bacteriocin production allows enterococci the ability to adapt to different
environmental conditions. Moreover, bacteriocins enriched during infection associated with
antibiotic resistance are different from bacteriocins associated with commensal enterococci
from healthy individuals (260).

Bacteriocins as Treatment Strategies
Bacteriocins produced by LAB have mainly been used and extensively studied in
biopreservation. However, more recently the interest for using bacteriocins for biomedical
applications has increased with investigations for the use of bacteriocins against pathogenic
microorganisms still gaining significance (261). Studies examining biomedical application of
LAB bacteriocins include efficacy analyses against systemic infections caused by S. aureus
and P. aeruginosa, oral infections caused by Streptococci, and vaginal infections caused by
Gardnerella vaginalis (262, 263).
One of the most extensively characterized bacteriocins is the lantibiotic nisin that is
produced by LAB (Lactococci and Streptococci) (264, 265). First characterized in Lactococcus
lactis isolated from fermented milk cultures, nisin is approved by the Joint Food and Agriculture
Organization/ World Health Organization (FAO/WHO) and the Food and Drug Administration
(FDA) for use as biopreservative (244, 265). Nisin A from Lactococcus lactis is a small (34
amino acids) cationic peptide that contains five lanthionine rings that are formed by dehydration
of precursor serines and threonines that react with neighboring cysteines to give lanthionine or
3-methyllanthionine that contain a thioether group (266).
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Nisin A targets lipid II, which is essential for bacterial cell wall biosynthesis and growth,
(267, 268). The high affinity for binding lipid II initiates pore formation in the membrane leading
to depletion of the membrane potential due to leakage of cellular content followed by cell death.
Nisin A has broad spectrum of activity against Gram-positive bacterial pathogens (foodborne
and non-food related) and Gram-negative bacteria when used in conjunction with antibiotics
(269, 270). Other natural variants of nisin have been identified from different Lactococcus spp.
and Streptococcus spp (270). Although, these natural variant share similar structure, slight
changes in the amino acid sequence alter the efficacy and target spectrum of these
bacteriocins, as seen with Nisin Z (271, 272). Moreover, bioengineered nisin variants have
enhanced activity against Gram-negative pathogenic bacteria, demonstrating the potential of
bacteriocins based therapeutic strategies (273).

Bacteriocins Active Against Candida spp.
Bacteriocins have traditionally only been tested for their antibacterial properties.
However, the prominence of nosocomial fungal infections resistant to traditional antifungals has
amplified the need for alternative treatment strategies, such as bacteriocin-based therapeutics.
A similar natural-variant of nisin A, nisin Z is produced by L. lactis NIZO22186 and significantly
inhibits in vitro growth and hyphal morphogenesis of C. albicans (271, 274). Additionally, nisin
Z inhibits hyphal morphogenesis and adhesion of C. albicans to oral gingival cell in an ex vivo
oropharyngeal candidiasis (OPC) model (275). Although nisin A and Z have similar
antimicrobial properties, there is a single residue change (H27N) that confers a superior
diffusion rate and increases solubility at neutral pH (272). This suggests that subtle changes in
bacteriocins can yield increased efficacy against fungal pathogens. However, other natural or
bioengineered variants of nisin have not been reported to have activity against C. albicans.
Lactobacillus plantarum, another LAB associated with fermented food, produces
multiple bacteriocins (class II) that comprise the plantaricin C11 complex, components of which
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have been reported to have fungicidal activity against C. albicans (276, 277). The plantaricin
C11 locus includes five operons: plnABCD, the three-component signal transduction system;
plnEFI, two bacteriocins (PlnE and F) and immunity factor; plnJKLR, two bacteriocins (PlnJ and
K) and immunity factors; plnMNOP, unknown function; plnGHSTUV, bacteriocin export
machinery (278). The mechanism of action for plantaricin C11 is similar to other bacteriocins of
its class, PlnEF and PlnJK target the membrane, create pores that disrupt the membrane
potential and lead to bacterial cell death (269, 279). Given the difference in cell wall anatomy of
Gram-positive bacteria and C. albicans the mechanism of action could vary. Treatment of C.
albicans with the different bacteriocins disrupted the membrane potential, however, PlnJ had
the greatest effect and caused release of potassium ions (K+) from cells. Additionally, all
plantaricin peptides increased reactive oxygen species (ROS) in C. albicans, suggesting that
plantaricins induce apoptotic cell death resulting in toxin-induced necrosis (277).

Antimicrobial Peptides Active Against C. albicans
Part of the innate immune response, antimicrobial peptides (AMPs) are differentially
expressed in response to pathogen-associated molecular patterns (PAMPs) that are
recognized by pattern recognition receptors (PRRs) present on host cells. AMPs from the major
classes, including cathelicidins, histatins, and defensins are demonstrated to be active against
C. albicans. Interestingly, AMPs have common characteristic found in bacteriocins (cationic,
amphipathic, positive net charge, structure stabilized by thiols), suggesting mechanisms of
action may overlap between AMPs and bacteriocins (266, 280).
The antimicrobial activity of histatin-5 (Hst-5) against C. albicans is the most extensively
examined of the AMPs that target C. albicans (281-283). Hst-5 is a cationic peptide found in
saliva providing the first line of defense against oral pathogens such as C. albicans. The
mechanism of action against C. albicans involves binding cell wall β-glycans and the cell wall
protein, Ssa1 and 2 (Stress-Seventy subfamily A), that allow for translocation of Hst-5 into the

46

cell via polyamide transporters (Dur3 and 31, Degradation of URea) (284-287). Inside the C.
albicans cell, Hst-5 has multiple intracellular targets that lead to disruption of mitochondrial
function, production of ROS, osmotic stress due to loss of potassium ion (K+), and then
ultimately cell death (288, 289).
LL-37 is a human cathelicidin that is derived by proteolysis of the CAP18 protein Cterminus and is produced by macrophages, neutrophils, keratinocytes, and mucosal epithelial
cells (290-292). Shown to have fungicidal activity against C. albicans, LL-37 associates with the
cell wall and/or membrane and binds to the cell wall protein Xog1 (β-1,3-exoglucanase) that
causes remodeling of the cell wall of C. albicans (293). Increased concentrations of LL-37
disrupt the cell membrane causing segregation of the membrane into small vesicles disrupting
the membrane potential due to loss of intracellular contents. The mechanism suggests that LL37 is able to remodel the membrane via Xog1 binding, thereby allowing for interaction with the
cell membrane and eventually disrupting the cell membrane and causing cell death (293-295).
Defensins are small (3.5 to 6 kDa) with three disulfide bridges and are grouped in two
classes, α-defensins and β-defensins (296, 297). Found in neutrophil granulocytes, α-defensin
(HNP-1) is active against C. albicans by non-lytic ATP efflux that depletes intracellular ATP
leading to cell death (298). β-defensins are larger and share little primary structure similarity,
but have very similar tertiary structures (297). Expressed in environmentally exposed epithelia,
β-defensin (hBD-3) has candidacidal activity against C. albicans by binding Xog1 which causes
cell wall remodeling similar to LL-37, without depletion of ATP (295).
AMPs are generally positively charged (+2 to +9), small peptides of 10 to 50 amino
acids that are frequently hydrophobic residues (≥30%). The structure of AMPs is important for
antimicrobial activity and many are amphipathic helices that form pores on bacterial
membranes (299). As reported, the mechanisms of action against C. albicans of these AMPs
are different and often require remodeling or transient interactions with the cell wall of
C.albicans. However, the structural conformation of these AMPs is important for interactions
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with the cells wall and membrane that initiate the mechanism of action (294, 296, 300).
Interestingly, sub-lethal concentrations of human LL-37, hBD-3 and Hst-5 reduce adhesion of
C. albicans to polystyrene (293, 295, 301, 302). LL-37 and hBD-3 also inhibit hyphal
morphogenesis at sub-lethal concentrations, suggesting that these AMPs could potentially
have clinical relevance in biofilm prevention (295, 302).
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CHAPTER 2:

Materials and Methods

Portions of this chapter are based on my first author publication. I have received permission to
reproduce data or text from this article. I have contributed significantly to this publication. The
article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin, and M. C. Lorenz. 2017.
Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and
virulence of Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 114: 4507–4512 (303).
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Strains and Culture Conditions
Bacterial and fungal strains used in this study are listed in Table 2.1. Media was
purchased from DIFCO and chemicals from Sigma, unless otherwise stated. Escherichia coli
strains were cultured in Luria Bertani broth overnight at 37°C with antibiotics where appropriate
using the following concentrations (µg/ml): kanamycin, 50; spectinomycin, 100; erythromycin
300. E. faecalis strains were cultured overnight at 37°C in Brain Heart Infusion (BHI) medium or
M9HY (304) with 100 μM glucose. Addition of antibiotics where applicable were at the following
concentrations (µg/ml): erythromycin, 50; and rifampicin, 100. Fungal strains were propagated
in yeast extract-peptone-dextrose (YPD) (305). All C. albicans biofilms were grown in artificial
saliva (YNB-AS) modified from Wong et al. (306) (0.17 % YNB (w/v), 0.5 % casamino acids
(w/v), 0.25 % mucin (w/v), 14 mM potassium chloride, 8 mM sodium chloride, 100 μM choline
chloride, 50 μM sodium citrate, 5 μM ascorbate).

Strain Construction
The entV mutant strain was constructed as previously described to create an in-frame
markerless deletion using a P-pheS* counterselection system (307). Briefly, sequences
flanking the 5’ and 3’ ends of entV were amplified by PCR. The 2 products were fused together
by PCR with primer-introduced NotI and Pst1 sites. The resulting fragment was ligated into
NotI/PstI digested pCJK47 vector, resulting in pCEG1. pCEG1 was electroporated into CK111
cells, and counterselection was completed to create strain CEG1F. Deletion of entV was
confirmed by PCR and sequencing. The entV complement strain was constructed using a
previously described strategy in which the wild type locus is regenerated with a silent mutation
in the gene to distinguish it from the original wild type strain (308). To generate entV*, a
mutation (CTT) was introduced into the leucine codon TTA corresponding to amino acid
position 50. The hyphal specific reporter strain (HWP1p::GFP) was transformed with plasmid
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pADH1-mcherry (ADH1p::mcherry) to construct a C. albicans strain expressing both hyphal
specific GFP and constitutive mcherry (309).

C. albicans Biofilm Assay
The C. albicans biofilm assay was developed using a similar technique as described
previously with the following modifications (42, 44, 310). C. albicans strains were grown
overnight at 30°C in YPD and washed three times with phosphate-buffered saline (PBS), and
the final OD600 was adjusted to 0.2 (~1 x 107 cell/ml) in PBS. Tissue culture treated 96 well
polystyrene plates (Corner) or chambered polystyrene slides (Ibidi) were inoculated with C.
albicans in PBS and incubated at 37°C for 90 minutes. Inoculated plates and slides were then
gently washed with PBS. After removal of PBS, YNB-AS was added with 50% bacterial
supernatant or sterile M9HY and incubated at 37°C for 24 to 48 hours. The supernatant of E.
faecalis (OG1RF, ΔfsrB, ΔentV, ΔentV/entV) was collected as previously described (115).
Biofilms grown with rEntV136 or sEntV68 were grown similarly with the peptide added to the
YNB-AS medium at the appropriate concentrations and compared to HEPES or DMSO vehicle
controls, respectively. After 24 to 48 hours of growth biofilms were washed three times with
PBS and hyphal morphogenesis and biofilm biomass were assessed.
Hyphal morphogenesis was quantified in C. albicans (HWP1::pGFP) biofilms grown in
96 well microplates by measuring GFP fluorescence, fluorescence intensity (excitation 488 nm,
emission 520 nm) was determined using a fluorescence microplate reader (SynergyMX,
Biotek). The relative fluorescence was calculated per well as a ration of GFP fluorescence to
cell density (OD600) and normalized to control treated biofilms (sterile medium, HEPES, or
DMSO). Biofilm biomass was determined by resazurin staining of C. albicans biofilms as
previously described (311), using 0.015mg/ml of resazurin for up to 1 hour in the dark.
For microscopic imaging, C. albicans biofilms were gently washed in PBS, as stated
above. Wild-type C. albicans (SC5341) were stained using 35 g/ml of calcofluor white for 5
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minutes in the dark and imaged using 4',6-diamidino-2-phenylindole (DAPI), Fluorescein
isothiocyanate (FITC), and differential interference contrast (DIC) filters on an Olympus IX81
automated inverted microscope with Slidebook software (version 6.0) or Nikon A1R Confocal
Laser automated inverted microscope system with NIS Elements (version 4.5).
All biofilm assays were done in triplicate for three independent experiments. The
different treatment types per experiment were compared by pairwise by Student’s t-test or OneWay ANOVA with a P value of <0.05 considered statistically significant using GraphPad Prism
(version 6.0).

Expression and Purification of Recombinant EntV
Hexahistidine-tagged EntV136 was expressed as described previously (312) with the
following modifications. The Coding regions of EntV (residues 35 to 171) were cloned in the
pET28a vector and transformed in to E. coli BL21 (DE3) cells. Cells were lysed in lysis buffer
(25 mM TrisHCl pH 8.0, 0.1 M sodium chloride, 1% (v/v) NP40, 10% (v/v) glycerol and 1 mM
PMSF) by sonication for 10 minutes on an ice water bath followed by centrifugation at 10,000 x
g at 4°C for 20 minutes.
The clarified lysate was then loaded on to a pre-equilibrated TALON affinity resin
(Clontech) and washed three times with 10 column volumes each of wash buffer (50 mM
sodium phosphate, 100 mM sodium chloride, 10 mM imidazole). The hexahistidine-tagged
protein was eluted in elution buffer (50 mM sodium phosphate, 100 mM sodium chloride, 150
mM imidazole) and elution fractions were collected. Samples with purified protein were
combined and dialyzed against buffer containing 5 mM HEPES pH 7.0. The collected fractions
were then subjected to Tricine-SDS-PAGE and analyzed by western blot using anti-His
antibiodies (THETM, GenScript).
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Murine Macrophage Infection
The activity of sEntV68 against C. albicans was evaluated in the murine macrophage
infection model using the end point dilution assay (313, 314). Briefly, RAW264.7 murine
macrophages were seeded in a 96-well plate with RPMI 1640 with phenol red supplemented
with 10% fetal bovine serum (RPMI-10) at a concentration of 2.5 x 105 cells/ml per well and
incubated overnight at 37°C with 5% CO2. After overnight growth at 30°C in YPD, C. albicans
cultures were washed twice with PBS and resuspended at a concentration of 5 x 105 cells/ml in
RPMI minus phenol with 100 nM of sEntV68 or DMSO and incubated at room temperature (RT)
with shaking for 1.5 hours. The macrophage seeded 96-well plate was inoculated with serial
dilutions of the pretreated C. albicans cell suspension. Media only controls were prepared in
the same manner. The plates were incubated at 37°C with 5% CO2 for 15 hours. Fungal
biomass was determined by quantification of C. albicans microcolonies using the XTT assay as
previously described (315). Absorbance was read at 451 nm in a microplate reader
(SynergyMX, Biotek). Assays were performed with replicates in three independent
experiments.
Protection of macrophages by sEntV68 was examined by monitoring cytotoxicity of C.
albicans on macrophages using the CytoTox96 Non-Radioactive Cytotoxicity assay (Promega)
that measures release of lactate dehydrogenase (LDH) release (316). RAW264.7 murine
macrophages in RPMI-10 were seeded in a 96-well plate at a concentration of 2.5 x 105
cells/ml and incubated overnight at 37°C with 5% CO2. C. albicans cell suspensions were
prepared at 1.5 x 106 cells/ml in RPMI minus phenol with 100 nM of sEntV68 or DMSO and
incubated at RT with shaking for 1.5 hours. Media only controls were also prepared in the same
manner. The macrophage seeded plates were inoculated with the pretreated C. albicans cell
suspension and incubated at 37°C with 5% CO2 for 5 hours. LDH release was normalized to
chemically lysed macrophages and assays were performed with replicates in three
independent experiments.
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Hyphal morphogenesis of C. albicans in phagocytes was quantified after infection of
RAW264.7 murine macrophages as described above with the following modifications.
Macrophages were seeded on glass coverslips in 12-well plates at a concentration of 2.5 x 105
cells/ml and incubated overnight at 37°C with 5% CO2. Overnight cultures of CEG1C
(HWP1p::GFP; ADH1p::mcherry) were subcultured in YPD for 5 h at 30°C. Cells were collected
and washed with PBS, and diluted in RPMI minus phenol with 100 nM of sEntV68 or DMSO to a
concentration of 1.5 x 106 cells/ml and incubated at RT with shaking for 1.5 hours. Media only
controls were also prepared in the same manner. The macrophage seeded glass coverslips
were inoculated with the pretreated C. albicans cell suspension and incubated at 37°C with 5%
CO2 for 2 hours. The media was aspirated and cells were fixed in 2.7% paraformaldehyde (pH
7.5) for 15 minutes at 37 °C followed by washing twice with PBS. Images were captured using
Tetramethylrhodamine (TRITC), Fluorescein isothiocyanate (FITC), and differential interference
contrast (DIC) filters on an Olympus IX81 automated inverted microscope with Slidebook
software (version 6.0). Cell enumeration was performed using at least 10 different fields of view
and at least 200 cells per treatment from replicates in three independent experiments.

sEntV Toxicity Assay
Toxicity of sEntV68 on murine macrophages (RAW 264.7) and human cervical epithelial
cells (HeLa) was examined by monitoring cytotoxicity affects of C. albicans on macrophages
using the CytoTox96 Non-Radioactive Cytotoxicity assay (Promega). This assay measures
release of lactate dehydrogenase (LDH) release (32). RAW264.7 murine macrophages in
RPMI-10 and HeLa cells in Dulbecco’s Modified Eagle Medium with high glucose and 10% fetal
bovine serum (DMEM-HG-10) were seeded in a 96-well plate at a concentration of 2.5 x 105
cells/ml and incubated overnight at 37°C with 5% CO2. Media from the seeded plates was
replaced with media containing 10 μM sEntV68 and incubated at 37°C with 5% CO2 for up to 72
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hours. LDH release was measured every 24 hours and the percentage of maximum LDH was
calculated as a ratio of LDH from treated cells to LDH from chemically lysed cells.

Oropharyngeal Candidiasis Model
The efficacy of sEntV68 was tested in the oropharyngeal candidiasis (OPC) model as
previously described (317). Mice were immunosuppressed by injecting cortisone acetate
subcutaneously in the dorsum of the neck at a concentration of 225mg/kg of body weight one
day before inoculation, and subsequently on days 1 and 3 of the infection. Before inoculation,
with C. albicans mice were anesthetized with an intraperitoneal injection of 0.1 ml/10g of body
weight with 10mg/ml ketamine and 1 mg/ml xylazine and placed on pre-warmed hot water
blankets. C. albicans was grown at 30°C in YPD broth overnight and sub-cultured twice before
washing with PBS twice and preparing cell suspensions in Hanks’ balanced salt solution
(HBSS) at 1 x 106 cells/ml. Calcium alginate swabs were immersed in the C. albicans
suspension with 100 nM sEntV68 or DMSO for 5 minutes and then used to inoculate the mice
sublingually for 75 minutes.
The mice were monitored continuously for signs of waking up (movement of extremities
and/or blinking of the eyes) and were given additional doses of ketamine, as necessary
(without xylazine, 50 mg ketamine/kg of body weight). After inoculation mice were treated with
100 nM of sEntV68 or DMSO in the drinking water for the remainder of the experiment. Mice
were euthanized at 3 and 5 days post-inoculation. The tongues were excised for tissue
histology and assessment of the fungal burden.
Tongues were fixed in zinc-buffered formalin followed by paraffin embedding. Thin
sections of the tongues stained with periodic acid–Schiff (317). Tissue histology was observed
using a light microscope. Images were captured at 40X and histology quantified by measuring
the percentage of infected epithelium relative to the entire epithelial area (318). The complete
epithelial area and infected epithelium were measured from 40X images taken of the entire
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tissue section of each sample. For each image the total area of epithelium and infected
epithelium were measured using Image J (version 1.5). Measurements were totaled and
expressed as a percentage of total infected epithelium relative to the entire totaled epithelial
area.
For examination of fungal burden, quantitative PCR (qPCR) was utilized by amplifying a
269 basepair fragment of internal transcribed spacer 2 (ITS2) between the 5.8S and 28S
ribosomal RNA genes of C. albicans using 5.8S forward primer and 28S-1 reverse primer
(Table 2.1) (319, 320)38,39]. DNA was extracted using the Yeast DNA Extraction Kit (Thermo
Scientific) according to the protocol with the following modifications. A portion of tongue from
each mouse was homogenized in 300μl of Y-PER reagent for 8–10 second increments with
incubation on ice until samples were completely homogenized followed by incubation at 65°C
for 10 minutes. Samples were centrifuged at 13,000 x g for 10 minutes, supernatant discarded,
400ul of Reagent A and 400ul of Reagent B was added, vortexed, and incubated at 90°C for 3
hours. After treatment protein removal agent DNA was precipitated with isopropyl alcohol and
washed with 70% ethanol and resuspended in sterile ultra pure water.
The ITS2 fragment was amplified from the DNA extractions and qPCR was performed
with a CFX96TM Real-Time System with a C1000 TouchTM thermal cycler (BioRad). A standard
curve was generated using C. albicans genomic DNA ranging from 0.5–5000 pg. C. albicans
DNA was quantified using FastStart Universal SYBR Green master mix with ROX (Roche).
Reactions were set-up according to the manufacturer’s recommendations. To screen for
contamination and background fluorescence during qPCR amplification, no template controls
were used. Non-infected mouse tongues and extraction-negative controls were processed in
parallel with tissue samples to test for possible contamination during homogenization and
extraction.
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Proteolytic Cleavage of rEntV136 by GelE
Since EntV136 is larger than expected based on size exclusion centrifugation of the
inhibitory activity and GelE and SprE cleave E. faecalis surface and secreted proteins,
proteolytic cleavage of rEntV136 by GelE was examined. Proteolytic activity of GelE was
examined as previously described by Pinkston et al. (321). rEntV136 (30 μg/ml) was incubated
with increasing concentrations of purified GelE (1.5, 4.5, 15, and 30 μg/ml) in PBS at 37°C for
one hour. Samples were boiled at 100°C for five minutes in SDS-PAGE sample buffer with
BME to terminate the reaction. To evaluate cleavage of rEntV136, reactions were subjected to
Tricine-SDS-PAGE and stained with SYPRO Ruby (Lonza) protein gel stain and visualized
using a 300 nm UV transilluminator (322).

Homozygous Deletion Mutant Library Screens
To identify possible inhibitory targets of the morphogenesis pathways and stress
response pathways a C. albicans mutant library of homozygous deletions in non-essential
transcription factors was screened for resistance to E. faecalis supernatant. Biofilms were
grown in a 96-well microtitered plates in YNBM as described above. Biofilm biomass was
quantified using resazurine (Sigma), as a measure of biofilm biomass and was quantified using
a fluorescence plate reader. E. faecalis supernatant was harvested as described above and
50μl added to 96 well plates with 1μl of mutant culture and 50μl YNBAS. Biofilms were grown
for 24 hrs at 37°C with shaking (200 rpm) (42). The 50μl of E. faecalis supernatant was
replaced for 50μl of sterile bacterial medium as non-treatment controls for each mutant strain.
Resistance to supernatant was determined by comparing treated cells to non-treated controls.
Wildtype (SC5314) and the respective parent strains (SN152 and Day286) were tested in the
same manner. Statistically significance differences between treated cells and non-treated
controls was determined by Student’s t-test. Mutant strains that had no statistically significance
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differences between treated cells and non-treated controls were test in a secondary screen
using the in vitro biofilm protocol described above.

sEntV68-FITC localization on C. albicans
C. albicans SC5314 expressing constitutive mcherry (ADH1p::mCherry) were grown
overnight at 30°C in YPD with aeration. Overnight cultures were sub-cultured in YPD for 5 h at
30°C and washed three times with phosphate-buffered saline (PBS). Washed cells where
transferred to chambered polystyrene slides (Ibidi) at a final OD600 of 0.2 (~1 x 107 cell/ml) in
YPD with or without 100nM of sEntV68. Cells were grown for 1 hour at 30°C or 37°C with
aeration. To observe sEntV68 localization on hyphal cells, cells were grown at 37°C for 1 hour
prior to addition of sEntV68. sEntV68 localization was observed by fluorescence microscopy
(Olympus IX81) using slidebook 6 (3i, Intelligent Imaging Innovations).
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Table 2.1: Strains and Plasmids
Candida albicans Strains
Source or
reference

-

(323)

Designation

SC5314

Wild-type

DHC271

HWP1-GFP

ura3/ura3ENO1/eno1::HWP1p-GFP-URA3

SC5314

(324)

CEGC1

HWP1-GFP ADH1mCherry

ura3/ura3ENO1/eno1::HWP1p-GFP-URA3
RPS10/rps10::ADH1p-mCherry-SAT1

DHC271

This study

Parent

ura3::imm434/ura3::imm434
his1::hisG/his1::hisG
arg4::hisG/arg4::hisG
pRS-ARG4-URA3

BWP17

(325)

Parent

arg4::dpl200/arg4::dpl200
his1::dpl200/his1::dpl200
leu2::dpl200/leu2::dpl200
URA3/ura3

RM1000

(326)

Day286

SN152

JC50

JC52

Relevant genotype/characteristic

Parent

Strain

Prototroph

hog1Δ/Δ

ura3/ura3
his1/his1
hog1∆::LoxP/hog1∆LoxP-HIS1-LoxP
RPS10/rps10::CIp20

(327)

hog1Δ/HOG1

ura3/ura3
his1/his1
hog1∆::LoxP/hog1∆LoxP-HIS1-LoxP
RPS10/rps10::CIp20-HOG1

(327)

Other Fungal Strains
Species

Relevant genotype/characteristic

Source or
reference

MYA3404

Candida tropicalis

Prototroph

(328)

CLIB298

Candida glabrata

Prototroph

(328)

J941367

Candida parapsilosis

Prototroph

(328)

Strain

Enterococcus faecalis Strains
Strain

Designation

OG1RF

Wild-type

TX5266

ΔfsrB

CK111

Conjugative donor

CEGF1

ΔentV

CEGF2

ΔentV/ entV

Parent

Source or
reference

OG1

(329)

OG1RF

(201)

upp4::P23repA4, SpR

OG1Sp

(307)

Markerless deletion of entV; RfR FaR

OG1RF

This study

Reconstituted entV with a silent nucleotide
change, Δef1097 [entV*], RfR FaR

CEGF1

This study

Relevant genotype/characteristic
Gel+ Spr+ RfR FaR
fsrB in-frame deletion mutant (bp 79 to 684);
Gel- Spr- RifR FaR KanR

Escherichia coli Strains and Plasmids
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Strain
EC1000

Relevant genotype/characteristic
E. coli cloning host for pCJK47-based plasmids; provides RepA in trans

Source or
reference
(330)

DH5α

E. coli cloning host for routine cloning

Invitrogen

BL21
(DE3)

E. coli cloning host for routine cloning, suitable for protein expression

Invitrogen

CEGE1

BL21 (DE3) with pET28a containing entV136

This study

pCJK47

Plasmid for markerless exchange, oriTpCF10 and P-pheS*; EmR

pET28a

Recombinant expression vector, N-terminal His•Tag/thrombin/T7•Tag configuration
plus an optional C-terminal His•Tag sequence, IPTG or lactose inducible

(307)
Novagen
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CHAPTER 3:

The Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm
formation, and virulence of Candida albicans

Portions of this chapter are based on my first author publication. I have received permission to
reproduce data or text from this article through license number. I have contributed significantly
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin,
and

M.

C.

Lorenz.

2017.

Enterococcus faecalis

bacteriocin

EntV

inhibits

hyphal

morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci.
U.S.A. 114: 4507–4512 (303).
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Introduction:
The mucosal surfaces, such as the orogastrointestinal tract of mammals, are ideal
niches for microorganisms and it is here where the balance between microbe-microbe
interaction and the host play an important role (331-333). Most of the microorganisms in the
orogastrointestinal tract are benign or beneficial to the host. However, the status of the host is a
major determinant of microbial pathogenesis. As discussed previously, microorganisms
typically found as part of orogastrointestinal tract microbiome can cause life-threatening
infections. In order for this to occur the microorganisms must cross host protective barriers
and/or evade the immune response and must be capable of colonizing other host niches
throughout the body (9).
Although E. faecalis and C. albicans are part of the orogastrointestinal microbiome, they
are among the most important and problematic, opportunistic nosocomial pathogens (186, 235,
334). When the host defenses are compromised and/or the microbiome is altered, both are
capable of crossing anatomical barriers and evading the host immune response (335).
Furthermore, the ability to form biofilms is an important virulence trait of both E. faecalis and C.
albicans, as both are capable of forming biofilms on biotic or abiotic surfaces that complicate
treatment strategies (39, 336). Specifically, C. albicans forms formidable biofilms that can
exceed 200µm in depth and is often found in polymicrobial biofillms with bacteria that have
enhanced resistance to anti-microbial drugs and immune surveillance (39, 42, 149, 337).
Since C. albicans and E. faecalis occur in overlapping niches as commensals and are
commonly co-isolated during infection, it is plausible that diverse interactions exist between
these microbes. Using a Caenorhabditis elegans model infections model, we demonstrated
antagonistic interactions between C. albicans and E. faecalis (115). Attenuation of virulence is
observed in both microorganisms during co-infection of Caenorhabditis elegans. As illustrated
in Figure 3.1, these findings demonstrate a commensal-like interaction within this model host;
co-colonization with both microbes does not cause disease unlike individual colonization.
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Further characterization of the activity by which E. faecalis inhibited C. albicans virulence,
identified a secreted factor that exerts its protective effect by inhibiting C. albicans hyphal
morphogenesis and biofilm formation (115, 338).
Taking into account the interactions observed in the C. elegans model, environments
where these commensal-like interactions might occur in a more relevant mammalian host were
considered. C. albicans infections of the oral cavity occur in immunocompetent and
immunosuppressed individuals (339). Oropharyngeal candidiasis (OPC), a superficial fungal
infection of the oral cavity, is one such infection (339-341). OPC most commonly occurs in
immunocompromised individuals, such as those that on immunosuppressant drugs,
chemotherapy, or suffering from HIV/AIDS (342-344). In immunocompetent individuals, some
common risk factors include use of dentures, corticosteroid inhalers, cigarettes and broadspectrum antibiotics (345-347).
Formation of thick white plaques (biofilms) of C. albicans on the surface of the tongue,
buccal mucosa, soft palate and pharynx are the clinical manifestations of OPC (347). While
superficially infecting the oral cavity, C. albicans invades the oral epithelial cells by inducing
endocytosis of C. albicans by the epithelial cells and active penetration of epithelial cells (348351). Invasion of the oral epithelial by C. albicans causes cell damage that elicits production of
the proinflammatory response that in turn stimulates production of AMPs and recruitment
professional phagocytes (339, 341). Professional phagocytes, neutrophils and macrophages,
are crucial elements of the innate immune response to C. albicans during oral infections (352,
353). Depletion of neutrophils and elimination of macrophages in a murine OPC model
increased susceptibility to C. albicans infection (352).
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Figure 3.1: E. faecalis-C. albicans interactions during infection of Caenorhabditis
elegans.
During mono-infection (top, left) C. albicans has pathogenic association with the host, primarily
through the production of hyphal cells. As seen in the scanning electron (SEM) image (bottom,
left) C. albicans forms hyphal cells that are capable of disseminating throughout the nematode.
In the presence of E. faecalis during co-infection (top, right), C. albicans has commensal like
association with the nematode. Apparent in the SEM image (bottom, right) C. albicans and E.
faecalis are able to colonize the GI tract of the nematode and hyphal morphogenesis is
inhibited. Hyphal morphogenesis is inhibited by the presence of E. faecalis via production of a
secreted factor(s) (115).
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Here I identify the E. faecalis secreted inhibitory factor as EntV, a secreted bacteriocin with
reported antibacterial activity. When synthetically produced, this peptide inhibited C. albicans
hyphal morphogenesis and biofilm formation at sub-nanomolar concentrations. Furthermore,
EntV was active against mature biofilms, reducing the depth and biofilm biomass. EntV
significantly protected murine macrophages against C. albicans infection and was protective in
a murine model of OPC. As the rise of drug-resistant fungal infections threatens to undermine
the current small arsenal of available treatments, I propose that EntV, or similar compounds,
may offer a viable therapeutic alternative, either alone or in combination with existing antifungal
agents.

Results:
E. faecalis supernatant inhibits C. albicans hyphal morphogenesis and biofilm formation
E. faecalis secretes an inhibitor of C. albicans virulence and biofilm formation (115). To
facilitate identification of this inhibitor, I developed a C. albicans in vitro biofilm model in which
cells are grown on a polystyrene substrate in an artificial saliva medium (YNBAS, adapted from
(306)). This media supported biofilm growth over 24 hours (Fig. 3.2A and B), while
supplementation with supernatant from E. faecalis cultures decreased both biofilm biomass and
hyphal morphogenesis as compared to biofilms grown in medium alone (Fig. 3.2). The E.
faecalis-mediated inhibition was observed microscopically in biofilms stained with calcofluor
white (Fig. 3.2A and B) and quantitated using the redox reactive dye resazurin to measure
biomass (311) (Fig. 3.2C). The reduction in hyphal formation was assayed using a reporter
strain expressing a transcriptional fusion of the hyphal-specific HWP1 gene to GFP
(HWP1p::GFP) (Fig. 3.2D-F) (324). A direct correlation between decreases in HWP1-induced
fluorescence (Fig. 3.2F) and biofilm biomass (Fig. 3.2C) was
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Figure 3.2: E. faecalis supernatant inhibits C. albicans hyphal morphogenesis and
biofilm formation.
C. albicans biofilms grown for 24 hours in YNBAS. Representative images of C. albicans (strain
SC5314) biofilms in the (A) absence and (B) presence of E. faecalis supernatant and stained
with calcofluor white. (C) Biofilm density was quantified by measuring resazurin fluorescence.
Representative images of C. albicans hyphal reporter strain (HWP1p::GFP) in the (D) absence
or (E) presence of E. faecalis supernatant. (F) Hyphal morphogenesis was quantified by
measuring GFP fluorescence as a ratio to the OD600. Experiments were performed three times
and analyzed using Student’s t-test (****, p<0.0001).
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observed, which is in agreement with previous studies demonstrating that hyphal deficient
mutants have reduced biofilm biomass (354, 355).

EntV inhibition of hyphal morphogenesis and biofilm formation in C. albicans
Our previous studies in the C. elegans infection model suggested that the secreted
inhibitor is regulated by the Fsr two-component quorum sensing system mediated by the
Gelatinase Biosynthesis Activating Pheromone (GBAP) (115, 338). The Fsr system regulates a
number of virulence-related traits, including secreted proteases GelE and SprE, as well as a
bacteriocin identified systematically from the genome of strain V583 as ef1097 (356, 357).
ef1097 encodes a 170 amino acid pre-pro-peptide, and cleavage of the secretion leader
sequences results in the export of a 136-residue pro-peptide that has bactericidal activity
against Gram-positive bacteria (245, 358). Bacteriocins are typically named after the strain in
which they are found, and thus the ef1097 gene product was called enterococcin V583 and
enterocin O16 in previous publications (245, 358). However, because the gene is present in all
E. faecalis strains sequenced to date (245), we propose to name the gene product EntV, for
enterocin originally found in V583.
I hypothesized that EntV is the secreted inhibitor of C. albicans hyphal morphogenesis
and biofilm formation and tested this genetically. I constructed a deletion mutant of entV and
tested the supernatant for activity against C. albicans biofilms using the hyphal specific reporter
strain (HWP1p::GFP). Indeed, the biofilm inhibitory activity was lost in supernatants derived
from the entV mutant strain relative to those from the WT E. faecalis strain (Fig 3.3A),
confirming that EntV is necessary for the inhibition of biofilm formation. The mutant strain was
complemented by introducing the gene back into the endogenous locus with a silent mutation
to distinguish it from the original wild type strain (308). Supernatant from the complemented
strain inhibited biofilm formation as well as that of wild type E. faecalis.
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Figure 3.3: EntV inhibition of hyphal morphogenesis and biofilm formation in C.
albicans.
(A) C. albicans SC5314 biofilms grown for 24 hours in YNBAS with sterile media (M9HY) or
spent supernatant from wild-type and mutant E. faecalis strains. Hyphal morphogenesis was
quantified by measuring GFP fluorescence as a ratio to the OD600. The experiment was
performed three times and analyzed using one-way ANOVA (***, p<0.0008). (B) Biofilms were
grown with increasing concentrations of rEntV136 or sEntV68 and the IC50 calculated at 1000 nM
and 0.3 nM, respectively.
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To test if EntV136 was sufficient for the inhibitory activity, rEntV136 was expressed and
purified from E. coli with a hexa-histidine tag (Table 2.1). I detected rEntV136 biofilm inhibitory
activity with an IC50 of ~1000nM (Fig. 3.3B). Thus, the genetic and biochemical evidence
suggests that EntV is both necessary and sufficient for inhibition of C. albicans biofilm
formation. The 136-amino acid EntV is larger than the 3-10 kDa indicated by our preliminary
characterization. However, recent work from Dundar et al. suggests that EntV136 is further
processed in a GelE-dependent manner to a 7.2 kDa peptide encompassing the 68 carboxyterminal amino acids (EntV68) (245). This mature form has a predicted disulfide bond that
encompasses nearly the entire length of the active protein (from amino acid 4 to 65 of the 68
amino acid peptide) that is necessary for its anti-bacterial activity (245, 358). Attempts to
express and purify EntV68 were unsuccessful due to apparent toxicity in E. coli. To surmount
this obstacle, the peptide was synthetically produced (sEntV68) in a form that included a
disulfide between the cysteine residues. As seen in Fig. 3.3B, sEntV68 inhibited biofilms with an
IC50 of 0.3nM, and therefore was ~3,000-fold more active than the unprocessed form of the
peptide.

Characterization of sEntV68 inhibitory activity
To investigate the dynamics of C. albicans biofilms in the presence of sEntV68 I turned
to confocal microscopy, with which I could generate a 3-D projection allowing me to measure
the overall biofilm depth. When formed in the nutrient-poor artificial saliva medium, control
biofilms were 25-30 µm thick after 24 hours, but only 5-10 µm thick in the presence of sEntV68,
roughly the length of a C. albicans yeast cell (Fig.3.4A and B). I next examined the
effectiveness of sEntV68 against mature biofilms grown for 24 hours. As viewed by confocal
microscopy, when biofilms that had developed for 24 hours were treated with sEntV68, a
reduction in biofilm depth from ~30μm to ~15μm (Fig. 3.4A) was observed, indicating
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Figure 3.4: Characterization of sEntV68 inhibitory activity.
C. albicans SC5314 biofilms were grown with 0.01% DMSO or 100 nM sEntV68 added at
different time points during biofilm formation (‘-‘, not added; ‘0hr’, added at the beginning of the
experiment. (A) Representative image of 24 hour and 48 hour biofilms observed by confocal
microscopy. (B) Hyphal morphogenesis was quantified by measuring GFP fluorescence as a
ratio to the OD600 for three separate experiments (**, p=0.0058; ***, p=0.0005; ****, p<0.0001).
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that this peptide could dismantle mature biofilms. Correspondingly, when the HWP1p::GFP
reporter was used to measure hyphal morphogenesis, a decrease in signal was observed at 48
hours following treatment with sEntV68 at 24 hours compared to biofilms grown with the vehicle
control after 24 and 48 hours of growth (Fig. 3.4B).

Protection of Murine Macrophages by sEntV68 during C. albicans infection
C. albicans is readily phagocytosed by murine macrophages, whereupon it activates a
complex transcriptional and morphogenetic program that promotes fungal survival and results
in hyphal-dependent lysis of the macrophage (316, 359, 360). I asked whether sEntV68 could
protect phagocytes from fungal-dependent killing. In these experiments, C. albicans was
incubated with sEntV68 for 1.5 hours before being added to the macrophages. sEntV68 was also
added to the macrophage cell culture medium immediately prior to infecting with C. albicans. A
decrease in C. albicans survival was observed when the macrophage infection was carried out
with sEntV68 as compared to the control infections (Fig. 3.5A), suggesting that sEntV68 works in
synergy with murine macrophages to make C. albicans more sensitive to macrophage attack.
Additionally, I observed a significant decrease in macrophage cytotoxicity in the presence of
sEntV68 compared to the controls (Fig. 3.5B), suggesting that sEntV68 protects murine
macrophages during C. albicans infection. To assess whether sEntV68 inhibits hyphal
morphogenesis within macrophages I used a hyphal specific reporter strain (HWP1p::GFP)
constitutively expressing mCherry (ADH1p::mCherry). Cells treated with sEntV68 had a
decrease in hyphal growth and GFP fluorescence as compared to control treated cells (Fig.
3.5C and D). No toxicity of the peptide towards macrophages or HeLa cells was observed (Fig.
3.6A and B). Taken together these results suggest that sEntV68 protects murine macrophages
by inhibition of C. albicans hyphal morphogenesis.
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Figure 3.5: Protection of Murine Macrophages by sEntV68 during C. albicans infection.
(A) Murine derived macrophages (RAW264.7) were infected with C. albicans (HWP1p::GFP,
ADH1p::mCherry) at an MOI of one for one hour with 0.01% DMSO or 100nM sEntV68 followed
by fixation with paraformaldehyde and visualized by fluorescence microscopy. (B)
Filamentation of phagocytosed cells was scored after 2 hours of co-culture. At least 200 cells in
at least 10 different fields of view were counted per replicate and the experiment was repeated
three times. (C) Macrophage killing was evaluated using the LDH cell toxicity assay and the
percentage of killed macrophages calculated. (D) C. albicans survival in murine macrophages
was assessed using the XTT cell viability assay and the percent survival was calculated.
Statically significant differences were calculated using one-way ANOVA (* p<0.02).
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Figure 3.6: Activity of sEntV68 in mammalian cells.
Lactate dehydrogenase (LDH) was measured from (A) Murine macrophages (RAW 264.7) and
(B) Human cervical epithelial cells (HeLa) exposed to 10 μM sEntV68 or 1% DMSO for up to 72
hours. Cell toxicity was evaluated using the LDH release assay and the percentage LDH
calculated for replicates of three separate experiments.
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Efficacy of sEntV68 in the Murine Oropharyngeal Candidiasis Model
Recall, that C. albicans grows on the mucosal surfaces of the oral cavity as part of the
normal microflora. However, in patients with defective immune responses it can cause a
superficial infection and invade the epithelial layer causing oropharyngeal candidiasis (OPC)
that leads to increased morbidity (348-351). To test the efficacy of sEntV68 in host relevant
infection model, I used a murine OPC model (317). In this model, mice were given a sublingual
inoculation of C. albicans and then given sEntV68 or DMSO in sterile drinking water for up to 5
days. The mice were euthanized and tongues excised at day 3 and day 5 to examine the
histology and fungal burden. Control mice showed classical signs of OPC, including extensive
invasion of the epithelium by fungal hyphae, disruption of the outer layers of epithelial cells, and
infiltration of neutrophils (Fig. 3.7A). In contrast, mice that were treated with 100 nM sEntV68
has significantly reduced invasion; most fungal cells were in the yeast or pseudohyphal form,
indicating that the peptide can inhibit morphological differentiation in vivo as well (Fig 3.7A). To
provide a quantitative measure of the epithelial invasion, I scored the proportion of the
epithelium infected in multiple tongues from control or sEntV68-treated mice, as recently
described (318). This data demonstrates a clear difference in the extent of epithelial damage
between treated and control animals (Fig. 3.7B). Finally, I assessed fungal burden on the
tongues. Because of the significant morphological differences in the two conditions, I
considered that colony forming unit plating would not accurately reflect differences in burden
between the primarily yeast morphology in the sEntV68-treated animals and the multinucleate
and highly adherent hyphae in the controls. Instead, I quantitated fungal DNA using qPCR as
described (319, 320), which showed a significant decrease in fungal burden in peptide-treated
mice relative to control mice (Fig. 3.7C). These results indicate that sEntV68 is effective in a
complex mammalian infection model that simulates clinically relevant infection conditions.
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Discussion:
I observed a distinct antagonistic interaction between E. faecalis and C. albicans, in
which hyphal morphogenesis, an important virulence factor, is inhibited by a secreted
bacteriocin, EntV. Hyphal morphogenesis is important for many aspects of C. albicans
pathogenicity, including biofilm formation, resistance to phagocytes, and dissemination through
tissues (102, 361, 362). The implications of this inhibitory activity are clearly seen in the
decreased virulence of C. albicans cells exposed to this peptide in murine macrophages, and in
the mouse OPC model.
Biofilm-related infections pose numerous clinical challenges. Biofilms provide a
measure of protection to the microbes encased within them from phagocytic attack and
antibiotics (20). Protection of persister cells within the biofilm allows C. albicans to disseminate
to distant sites, seeding relapses and systemic infections (88). Biofilms of C. albicans are
robust and form both on implanted medical devices (catheters, heart valves, dentures) and on
epithelial surfaces (OPC) (39). Our in vitro experiments were designed to model the oral cavity,
and I observed biofilms exceeding 50 µm in depth; in other media conditions, they can be
greater than 200 µm thick. Often, device removal is the only effective treatment option, though
this may not be feasible or desirable given a patient’s underlying conditions. Agents that
directly disrupt biofilms would be very useful chemotherapeutics in conjunction with existing
drugs. Our work suggests that EntV is a candidate anti-biofilm agent.
Currently, nearly all antimicrobials in clinical use work by killing or preventing the growth
of the infectious agent. Certainly, this is true for C. albicans. There are presently only three
families of commonly used antifungal drugs, polyenes, azoles and echinocandins, all of which
target the cell membrane or the cell wall (80, 363). Resistance to this limited arsenal of
antifungals is a growing problem (364). It has long been speculated that therapeutics that target
virulence might effectively treat infection and not select for resistance as strongly as traditional
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antimicrobials. In support of this idea, a small molecule also exhibiting C. albicans biofilm and
hyphal morphogenesis-inhibiting properties did not induce resistance after repeated exposure
(365).
Many clinical Candida infections are polymicrobial. In one survey of these polymicrobial
infections, the most common bacterial co-habitant was E. faecalis (109). In contrast, our work
suggests that these two microbes have evolved a relationship in which one inhibits a key
virulence trait of the other. A precedent for this apparent contradiction is seen in the interaction
between C. albicans and P. aeruginosa, species that are antagonistic in vitro (126, 128), but
are associated with significantly worse outcomes when found together in patients, including the
lungs of cystic fibrosis patients, during ventilator-associated pneumonia, and in burn trauma
(123, 124).
I previously speculated that the presence of both C. albicans and E. faecalis might
promote a commensal interaction with the host, in which virulence attributes are suppressed to
facilitate colonization (Fig.1) (338). C. albicans ability to colonize the GI tract in a
nonpathogenic state and switch to a pathogenic state upon disruption of the host immune
response or microflora has been well documented (4, 8, 11). However, C. albicans is able to
shape the bacterial microflora during antibiotic recovery. In a murine colonization model C.
albicans reduced Lactobacillus spp. and promoted E. faecalis colonization after antibiotic
treatment (366, 367). These data thus suggest a model in which C. albicans and E. faecalis
promote

each

other’s

commensalism

during

nonpathogenic

colonization

of

the

orogastrointestinal tract, but when the status of the host immune response is disrupted,
invasive infection might be stimulated.
We are only beginning to understand the complex interactions amongst the microbiota
and their varied effects on the human host, but the knowledge is likely to have important
impacts on the development of novel antimicrobials. In conclusion, I report the identification of
an anti-fungal, virulence-targeting compound, EntV68, which does not slow the growth of C.
albicans, even at high concentrations, but can elicit protection in the sub-nanomolar range by
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inhibiting hyphal morphogenesis. This study provides impetus for further discovery of novel
antimicrobial therapeutics with virulence-targeting activity.
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CHAPTER 4:

Post-Translational Processing of EntV influences the inhibition of hyphal
morphogenesis and biofilm formation of Candida albicans

Portions of this chapter are based on my first author publication. I have received permission to
reproduce data or text from this article through license number. I have contributed significantly
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin,
and

M.

C.

Lorenz.

2017.

Enterococcus faecalis

bacteriocin

EntV

inhibits

hyphal

morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci.
U.S.A. 114: 4507–4512 (303).
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Introduction:
Bacteria use quorum sensing to communicate via accumulation and detection of
extracellular signaling molecules that enable them to respond to these environmental cues
based on cell density (368). Gram-positive bacteria QS signaling molecules are peptides that
are post-translationally processed from propeptides. These peptides bind the extracellular
receptors on specific transmembrane proteins that trigger specific signal transduction pathways
(369).
The Accessory gene regulator (Agr) system in Staphylococcus Spp. is one of the moststudied cyclic peptide-mediated QS systems found in Gram-positive bacteria (Novick &
Geisinger, 2008). The autoinducing peptide (AIP) is produced from the propeptide AgrD that is
post-translationally processed and secreted by the transmembrane peptidase AgrB. Upon
accumulation of AIP, the canonical two-component system consisting of the histidine kinase
(AgrC) and response regulator (Agr A) transduces the signal that results in phosphorylation of
AgrA (370-374). Phosphorylation activates AgrA, which positively regulated gene expression.
This type of QS system is widespread among Gram-positive bacteria, cognate gene cluster
containing these four components have been identified in Enterococcus, Listeria, Clostridium,
Lactobacillus, and Bacillus spp., suggesting the retention of this type of QS system is important
for the survival of many Gram-positive bacteria (371, 372, 375, 376).
A homolog of the Agr system, the Fsr system in E. faecalis regulates expression of
pathogenicity-associated genes and is important for virulence in different infection models (197,
201, 202, 377, 378). The fsr gene cluster contains four genes that encode a histidine kinase
(FsrA), response regulator (FsrC), transmembrane peptidase (FsrB), and the cyclic signal
peptide GBAP (FsrD) (376). Phosphorylated FsrA directly regulates the fsr genes, gelE, sprE,
and entV and indirectly regulates genes involved in autolysis, adhesion, and biofilm formation
(201, 356, 376, 379). Using microarray transcriptional profiling, Bourgogne et. al. (356) found
that fsrB influences expression of numerous genes throughout the growth phases of E.
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faecalis. In addition to the Fsr regulon, gelE, sprE, and entV all contain consensus sequences
necessary for FsrA binding and expression is dependent on cell density where an increase in
gene expression is seen in late log phase (356).
Here I demonstrate the post-translational modifications of EntV necessary for inhibition
of C. albicans hyphal morphogenesis and biofilm formation. The mature inhibitory activity was
3-10 kDa and a synthetic peptide containing the C-terminal 68 amino acids was functional,
indicating that the EntV protein is post-translationally processed via proteolytic cleavage. I
show here that recombinant EntV is cleaved in vitro by GelE. Furthermore, EntV is predicted to
have a disulfide bond and reduction and alklylation of the supernatant abolished inhibitory
activity. Finally, characterization of EntV structure and activity provides useful insight for the
future design of novel antifungal and antibiofilm therapeutics based on EntV inhibitory activity
against C. albicans.

Results:
Characterization of E. faecalis supernatant inhibitory activity
To characterize the activity of the inhibitor, I used the C. albicans in vitro biofilm model I
developed using polystyrene as the growth substrate grown in YNBAS (306). Biofilms grown for
24 hours in the presence of supernatant from E. faecalis had decreased biomass and hyphal
growth as compared to biofilms grown in medium alone (Fig 4.1.). This inhibitory activity was
retained in the E. faecalis supernatant fraction between 3 to 10 kDa that had been boiled for 20
minutes at 100°C (Fig. 4.1), consistent with what was seen in the C. elegans infection model
(115). In addition, the inhibitory activity was abolished with proteinase K treatment, suggesting
a small (3 to 10kDa), heat-stable protein is responsible for the inhibitory activity observed in
both the in vitro biofilm model and the in vivo C. elegans infection model.
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Figure 4.1:. Characterization of inhibitory activity from E. faecalis Supernatants.
C. albicans (HWP1p::GFP) biofilms grown at 37°C for 24 hours in YNBAS. Hyphal
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD600.
Inhibitory activity from E. faecalis supernatant was retained between 3-10 kDa after size
exclusion centrifugation. A reduction of inhibitory activity was observed in supernatants treated
with proteinase K and from deletion mutants of fsrB or entV. Experiments were repeated at
least three times and statistically significant differences relative to treatment with the WT
supernatant were calculated using a one-way ANOVA, and are indicated by asterisks (**,
p<0.006; *, p<0.01).

82

Post-translational processing of EntV
As discussed previously (Chapter 1), the inhibitory activity was lost with disruption of the
Fsr system and deletion of entV (Fig. 3.3A). Furthermore, deletion of gelE or sprE resulted in
decreased inhibitory activity and a double deletion of gelE and sprE further decreased inhibitory
activity, indicating that GelE and SprE are necessary for maximum inhibitory activity. According
to the entV gene sequence, EntV is slightly larger than the inhibitory factor characterization
based on size exclusion centrifugation (Fig. 4.2). Proteolytic processing of EntV is a plausible
explanation for this size discrepancy. Since GelE and SprE cleave E. faecalis surface and
secreted proteins, they are candidates for processing EntV (321, 379).
To test the hypothesis that GelE and/or SprE proteolytically process EntV, in silico and
in vitro tests were performed. A member of the M4 family of proteases thermolysin, a homolog
of GelE from Bacillus thermoproteolyticus, preferentially cleaves sites with position P1' that
have bulky and aromatic residues (Ile, Leu, Val, Ala, Met, Phe) and aromatic sites in position
P1 [392]. Glutamyl endopeptidases V8 from Staphylococcus aureus is a homolog of serine
protease (SprE) from E. faecalis and preferentially cleaves at Glu in position P1, Pro/Val or Phe
in position P2, Ala/Val in position P3, and Asp in position P4 (380). Thus, proteolytic cleavage
of EntV by these homologous proteases was examined in silico using PeptideCutter (ExPasy)
[394].
EntV contains two cysteines that form a putative disulfide bond that is necessary for
bactericidal activity (358). To examine the role of the disulfide bond for activity against C.
albicans, E. faecalis supernatant was reduced followed by alkylation to permanently reduce any
cysteine in the supernatant. As illustrated in Figure 4.3A, a reduction in the inhibitory activity of
WT supernatant was observed after reductive-alkylation, suggesting that the disulfide bond is
also necessary for the inhibitory activity against C. albicans. Disulfide bond formation in Grampositive bacteria has been understudied and is not fully understood. On the other hand disulfide
bond formation in Gram-negative bacteria has been extensively studied. Since Gram-positive
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Figure 4.2: The E. faecalis Fsr system is involved in regulating the inhibitory activity.
The Fsr two component quorum-sensing system from E. faecalis regulates expression of EntV
and secreted proteases (GelE and SprE) (356). C. albicans (HWP1p::GFP) biofilms grown at
37°C for 24 hours in YNBAS. Hyphal morphogenesis was quantified by measuring GFP
fluorescence as a ratio to the OD600. Disruption of gelE and/or sprE decreased inhibitory
activity. Experiments were repeated at least three times and statistically significant differences
relative to treatment with the WT supernatant were calculated using a one-way ANOVA, and
are indicated by asterisks (**, p<0.009).
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bacteria lack traditional periplasmic spaces it has been thought that these disulfide bonds are
formed spontaneously upon secretion or that many Firmicutes secrete few, if any, proteins that
have disulfide bonds (381). However, recent studies have demonstrated the importance of
disulfide bond formation by thiol-disulfide oxidoreductases (DsbA-like proteins) in Grampositive actinobacteria (382). Interesting, disruption of dsbA by transposon mutagenesis also
resulted in reduced inhibitory activity (Fig. 4.3A). Taken together these results demonstrate that
protein oxidation is necessary for maximum inhibitory activity, which suggests that proper
formation of the disulfide bond is necessary for EntV efficacy.
Disulfide bridges stabilize the formation of β-strands and α-helices, can control
substrate accessibility, and protect proteins from damage. Therefore, only cleavage sites
outside of the disulfide bonds are shown (383-385). As illustrated in Figure 4.3B, GelE cleaves
at A68 and SprE cleaves at residues further toward the N-terminus, which corresponds with
previous MS/MS analysis and N-terminal degradation sequencing of EntV from WT E. faecalis
(245). Thus, these data suggest that GelE is important for cleavage of the EntV propeptide to
produce the active bacteriocin. Additionally, GelE also cleaves the C-terminus of EntV in silico
resulting in production of a 65 amino acid peptide of 6.9 kDa in size (Fig. 4.3B).
To investigate further the proteolytic processing of EntV by GelE, recombinant EntV136
(136 amino acid propeptide) expressed and purified from E. coli (BL21-DE3) was incubated
with increasing concentrations (1.5, 4.5, 15, and 30 μg/ml) of purified GelE from E. faecalis
(321). I observed increased amounts of lower molecular weight EntV (~7KDa) with increased
concentrations of GelE (Fig. 4.4), indicating proteolytic processing of EntV by GelE. This
supports previous reports that demonstrate the propeptide (136 amino acids, ~15kDa) is further
modified by the extracellular gelatinase into the active bacteriocin of 68-amino acid (7kDa)
peptide that has been shown to be active against bacteria (245). As discussed in Chapter 3, I
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Figure 4.3: Protein oxidation is important for inhibitory activity.
(A) C. albicans (HWP1p::GFP) biofilms grown at 37°C for 24 hours in YNBAS. Hyphal
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD600.
Reductive-Alkylation decreased inhibitory activity of WT E. faecalis supernatant. Disruption of
dsbA (predicted dithiol-disulfide isomerase) by transposon mutagenesis also decreased
inhibitory activity. Experiments were repeated at least three times and statistically significant
differences relative to treatment with the WT supernatant were calculated using a one-way
ANOVA, and are indicated by asterisks (**, p<0.01, ***p<0.001). (B) In silico digestion of EntV
by GelE homolog thermolysin (T) and SprE homolog glutamylpeptidase (G) using
PeptideCutter (ExPASy) (242).
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Figure 4.4:. EntV is proteolystically processed by E. faecalis gelatinase.
GelE cleavage of rEntV136 was analyzed by SDS-PAGE. Increasing amounts of purified GelE
was incubated with 30μg/ml rEntV136 N-terminally tagged with hexa-His for 1hr and the
reactions terminated by addition of SDS-PAGE sample buffer and boiling. Proteins were
stained with SyproRuby (Lonza) and visualized using a 300 nm UV transilluminator. Increased
concentrations of GelE resulted in production of smaller molecular weight products (>10kDa).
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demonstrated this processed peptide of 68-amino acid inhibited hyphal morphogenesis, biofilm
formation, and virulence of C.albicans.
Classification and structure of E. faecalis bacteriocin EntV
EntV belongs to the class IIIb bacteriocins, which are the larger (>10kDa), non-lytic
bacteriocins produced by Gram-positive bacteria [400]. To date only five bacteriocin have been
identified and characterized in this class, dysgalacticin (DysA, Streptococcus dysgalactiae
subsp. equisimilisI), SA-M57 (Streptococcus pyogenes M-type 57), EntV (E. faecalis), and
YpkK (Corynebacterium jeikeium) (243, 358, 386). Each of these proteins have conserved
secondary structures: (1) unstructured N-terminus, (2) helix-loop-helix motif at the C-terminus,
and (3) two cysteine residues that form a putative disulfide bond (242, 243, 358, 386) (Fig. 4.5A
and B). In Addition, these class IIIb bacteriocins have a non-lytic mode of action against similar
Gram-positive bacteria and only EntV has been test against fungi (245, 358).
I hypothesized that these other bacteriocins similar to EntV are also proteolytically
cleaved by proteases of the M4 family, homologs of thermolysin, aurolysin and gelatinase
(GelE). As seen in Table 4.1, M4 family proteases have been identified in these other bacterial
species and proteolytic cleavage by thermolysin was observed in silico (387). Furthermore, all
of the class IIIb bacteriocins gain a greater positive charge that is characteristic of efficacious
antimicrobial peptides (Table 4.1, ProtParam) [403]. Using the protein structure of dysgalacticin
in consort with the secondary structure consensus (PROMALS3D) of the class IIIb bacteriocins
the predicted tertiary structure was assembled (I-Tasser) (242, 388). Collectively, these results
suggest that the class IIIb bacteriocins are post-translational processing into small (<10kDa),
positively charged, amphipathic bacteriocins.
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proteolytic processing.
The first amino acid was determined by in silico digestion of each bacteriocin with M4 family
protease thermolysin (PeptideCutter, ExPASy). All bacteriocins have conserved cysteines
involved in disulfide bond formation. (A) ClustalW alignment of EntV, SA-M57, DysA, and YpkK
bacteriocins (242, 358). * indicates conserved amino acids; : indicates amino acids with
strongly similar function; and . indicates amino acids with weakly similar function (Network
Protein Sequence Analysis, NPS) (358). (B) Multiple alignment with predicted secondary
structure of EntV, SA-M57, DysA, and YpkK bacteriocins (PROMALS3D) (389). The
conservation indices for positions with a conservation index above 4 are shown at the top of the
alignment block. Sequences are colored according to predicted secondary structures (red:
alpha-helix). Just below the alignment sequence is the consensus amino acid symbols:
conserved amino acids are in bold and uppercase letters; aliphatic (I, V, L): l; aromatic (Y, H,
W, F): @; hydrophobic (W, F, Y, M, L, I, V, A, C, T, H): h; polar residues (D, E, H, K, N, Q, R, S,
T): p; tiny (A, G, C, S): t; small (A, G, C, S, V, N, D, T, P): s; bulky residues (E, F, I, K, L, M, Q,
R, W, Y): b. Below the consensus amino acid symbols are the consensus predicted secondary
structure symbols (alpha-helix: h).
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Table 4.1. Computation of physical and chemical properties of class IIIb bacteriocins.
Based on the sequence analysis of the propeptide and proteolytically processed active peptide
the size and theoretical pI was calculated using ProtPram (ExPASy). Identification of M4 family
proteases was preformed using the NCBI gene database.

Species

Bacteriocin

Gene

M4 Family Protease

E. faecalis

Enterococcin V

entV

Gelatinase (gelE)

S. dysgalactiae

Dysgalacticin

dysA

Oligoendopeptidase F (pepF)

S. pyogenes

SA-M57

scnM57

Peptidase F (pepF)

C. jeikeium

Corynicin JK

ypkK

Zn-dependent metalloprotease (JKRS06030)

Bacteriocin

Propeptide Size
(kDa)

Theoretical pI

Active Peptide Size
(kDa)

Theoretical pI

Enterococcin V

14 (136 a.a.)

4.87

6.9 (65 a.a.)

9.84

Dysgalacticin

16.8 (152 a.a.)

4.77

7.0 (65 a.a.)

9.75

SA-M57

14.4 (137 a.a.)

5.40

7.3 (68 a.a.)

9.60

Corynicin JK

21.5 (192 a.a.)

4.46

6.0 (58 a.a.)

9.24
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Discussion:
Important for competition and commensal growth in the GI tract of the host, posttranslational processing of bacteriocins is common for efficient production of antimicrobial
peptide against bacteria and fungi (390). Here I demonstrate that EntV is processed in an Fsrdependent manner into a mature form of 68 amino acids that has activity at nanomolar or lower
concentrations in most of our assays, demonstrating that it is highly efficacious.
EntV is a bacteriocin that belongs to the class IIIb bacteriocins, which are the larger
(>10kDA) bacteriocins (391). The structure of the mature form of EntV is predicted in silico to
consist of two helical elements, separated by a flexible loop region. The conserved cysteines
located immediately before and after these two helices are thought to form a disulfide bond
(392, 393). The immature form contains an additional N-terminal segment predicted to be
unstructured (245), which is removed by GelE to form the mature and active form of the peptide
(245). While many bacteriocins encode an immunity protein, Dundar et al. could find no
evidence of one, and E. faecalis appears to be intrinsically resistant (358). The bacteriocidal
activity of EntV against sensitive species is not due to lysis, and the mechanism remains
enigmatic (242).
The class IIIb bacteriocins that have been identified to date have a similar predicted
secondary, though are not well conserved at the amino acid level. Considering the structure
similarity and conserved cysteines necessary for activity and in silico cleavege, it is plausible
that these other class IIIb bacteriocins, like EntV are also post-translational modified resulting in
production of a smaller (<10kDA) highly active positively charged antimicrobial peptide. Thus,
characterization and classification of these bacteriocins may need revision (242, 243, 358,
394). EntV-like bacteriocins have been identified in multiple host-associated bacteria
suggesting these bacteriocins are important for both pathogenic and commensal association
with the host (303). Furthermore, given the physiochemical similarities of these bacteriocins it is
possible that they have overlapping target spectra. This remains to be further tested and
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suggests that these bacteriocins may play an important role in bacterial-fungal interactions in
other Gram-positive bacteria.
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CHAPTER 5:

Assessment of EntV mechanism of action against C. albicans

Portions of this chapter are based on my first author publication. I have received permission to
reproduce data or text from this article through license number. I have contributed significantly
to this publication. The article is listed for reference: Graham, C. E., M. R. Cruz, D. A. Garsin,
and
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Lorenz.

2017.
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morphogenesis, biofilm formation, and virulence of Candida albicans. Proc. Natl. Acad. Sci.
U.S.A. 114: 4507–4512 (303).
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Introduction:
C. albicans biofilms are complex, structured communities that form on biotic and abiotic
surfaces and are a growing concern in the clinical setting. One of the leading opportunistic
fungal pathogens, C. albicans biofilms are often difficult to eradicate and can lead to more
severe systemic infection if left untreated. Comprised of both yeast and hyphal cells C. albicans
biofilms form via a highly regulated process that begins with adhesion, followed by initiation and
formation of hyphal cells, then maturation, and ultimately dispersion (Fig. 1.1) (41).
Adherence is the first essential stage in C. albicans biofilms development and is a
highly regulated process. Factors such as cell surface composition, extracellular matrix
production, adhesins and other cell surface proteins are all coordinated during attachment to a
substrate. Finkel et al. (395), identified 30 transcriptional regulators that are important for
adherence during biofilm development, which regulate the expression of 37 surface-associated
genes among other genes. Furthermore, a functional relationship between cell wall stress
responses and regulation of adherence was identified recently. Transcriptional repression of
ARC18, a member of the Arp2/3 complex important for regulation of endocytosis and the actin
cytoskeleton, resulted in reduced adhesion and biofilm formation (395). Additionally, cell
surface hydrophobicity and exposure of cell wall chitin and β-glucans was increased with
depletion of the Arp2/3 complex leading to impaired cell wall integrity and activation of Rho1mediated cell wall stress responses (50, 396-398).
C. albicans cell wall proteins are essential for maintaining cell wall integrity, adherence,
enzymatic functions, biofilm development, and morphological transition. In C. albicans, a MAPK
network regulates responses to environmental stresses such as changes in temperature,
osmolarity, ionic stress, cell wall stress, and oxidative stress. Three interconnected MAPK
pathways, Hog1, Mkc1 and Cek1, regulate this core transcriptional response to environmental
stress (50, 398-400). Different membrane sensors sense environmental stress signals; the
signals are transduced via the MAPK pathways, resulting in cooperative phosphorylation of
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Hog1 and Cek1 followed by phosphorylation of Mkc1. Collectively, this results in generation of
a core transcriptional stress response (3). While components of the core stress responses have
been identified many of the sensors have not been identified or remain uncharacterized in C.
albicans.
I hypothesize that EntV is eliciting a cell surface stress that disrupts cell surface
proteins, adhesion and thus biofilm formation and hyphal morphogenesis. Here I identify C.
albicans genes that when deleted decrease sensitivity to E. faecalis inhibitory activity during
biofilm development. Deletion in genes involved in regulation of hyphal morphogenesis, cell
wall stress, and cell wall architecture were identified. Furthermore, assessment of sEntV68
localization by fluorescence microscopy in yeast and hyphal cells demonstrated surface
association in all cell types. Although sEntV68 inhibits hyphal morphogenesis, biofilm formation
and virulence of C. albicans, sEntV68 did not kill C. albicans, nor inhibit its growth, even at high
concentrations. sEntV68 inhibits hyphal morphogenesis and biofilm formation in clinical isolates
of C. albicans, as well as other pathogenic Candida spp. EntV68, or similar compounds, may
offer a viable therapeutic alternative. Understanding the mechanism of action is important for
development and use of EntV68 based therapeutics. Identification of genes dysregulated by E.
faecalis will provide insight into possible gene targets for development of therapeutic strategies
that target hyphal morphogenesis and biofilm development (303).

Results:
Role of hyphal morphogenesis and surface stress response
E. faecalis secretes an inhibitor of C. albicans virulence and biofilm formation that I
have identified as the bacteriocin EntV (23, 42, 49). Hyphal morphogenesis was reduced in
both in vitro and in vivo assays, suggesting that the E. faecalis mediated inhibition C. albicans
is due to dysregulation of hyphal morphogenesis pathways. Thus, I hypothesized that E.
faecalis dysregulates hyphal-specific genes in C. albicans that are important for hyphal
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morphogenesis and thus biofilm development. As mentioned previously, hyphal morphogenesis
and biofilm formation of C. albicans are interconnected and regulated by the Ras1-cAMP-PKA
signal pathway (401, 402). This is important when considering the mechanism of action of E.
faecalis-mediated inhibition of hyphal morphogenesis and biofilm formation.
To understand the mechanism of action I assessed C. albicans mutant libraries of
transcription factors and cell wall proteins (303) for decreased sensitivity to E. faecalis
supernatant. Biofilms were grown as described above using the resazurin redox assay to
quantify biofilm biomass (401). Resistance to WT E. faecalis supernatant was determined by
comparing supernatant treated cells to media treated controls. Homozygous deletion mutants
in non-essential transcription factors and cell wall proteins that were resistant to E. faecalis
supernatant are listed in Table 5.1. Theses homozygous deletion mutants have known
functions in hyphal morphogenesis, cell wall biogenesis, mating, cell cycle and unknown
function.
24 Transcription factor mutants were identified that were less sensitive to E. faecalis
supernatant (Table 5.1) (401, 403, 404). Some of the transcription factor mutants identified are
involved in negatively regulating hyphal morphogenesis (NRG1, SSN6, RAP1), deletion of
these genes results in a hyperfilamentous phenotype (400, 405). Transcription factor mutants
identified involved in cell wall biogenesis genes and that are linked to the cell wall integrity
(CWI) or Hog1 stress response signal cascades (CAS5, SKO1, FCR1, ORF19.2476) were also
identified (398, 406, 407). 15 cell wall protein deletion mutants were identified that decreased
sensitivity to E. faecalis supernatant (Table 2.2). Moreover, cell wall protein deletion mutants
identified are also linked to hyphal morphogenesis (PDE2) and surface stress response
(WSC1, WSC2, WSC4, PGA26, CCW14, ECM4) (107). Taken together these data suggest E.
faecalis supernatant is triggering an adaptive stress response in C. albicans that leads to
repression of morphogenesis (49).
The Ras1-cAMP-PKA signal pathway regulates hyphal morphogenesis during biofilm
development (48). Therefore, inhibition of C. albicans biofilm formation would likely involve

96

Table 5.1: Homozygous deletion mutants in non-essential transcription factors resistant
to E. faecalis supernatant.
C. albicans homozygous deletion mutants were screened for resistance to E. faecalis
supernatant biofilm inhibition. Biofilms were grown in YNBAS for 24 hours and biofilm biomass
was quantified using the resazurin redox assay comparing biofilms grown in the presence or
absence of WT E. faecalis supernatant.

S. cerevisiae
Ortholog
HMS1
GLN3
AZF1
PHO2
LYS14
MOT3
RDS2
MBP1
ADR1
UME6
BAS1
STP3
SKO1
CRZ1
ECM5
MSN2
CYC8
CAT8
NRG2
RIM101
HMS1
KAR4
RAP1

Gene

Systematic Name

Function

HMS1
GLN3
C5_04410C_A
GRF10
ZCF21
CAS5
CWT1
MBP1
TRY4
WOR2
C2_05640W_A
STP4
SKO1
CRZ2
C1_05750C_A
MSN4
SSN6
FCR1
NRG1
RIM101
AAF1
CPH2
KAR4
RAP1

C5_00670C_A
C5_04280C_A
C5_04410C_A
C5_05080W_A
C4_00760W_A
C4_01190W_A
CR_05530C_A
C3_04110C_A
C3_05050W_A
C3_05170W_A
C2_05640W_A
C2_03220C_A
C1_03770W_A
CR_07060C_A
C1_05750C_A
C1_08940C_A
C3_07020W_A
C3_06850W_A
C7_04230W_A
C1_14340C_A
C3_06470W_A
C6_00280W_A
CR_02330C_A
C2_10080W_A

Gene

Systematic Name

S. cerevisiae
Ortholog

Function

PGA26
PGA7
PDE2
WSC1
WSC2
WSC4
MNN4-4
MNN10
MP65
CCW14
VTI1
ECM4
ECM21
ECM25
SAP98

C1_05760C_A
C4_00120W_A
C1_02840W_A
C3_04250W_A
C6_02670C_A
C1_14360C_A
C6_02830W_A
C4_00310C_A
C2_10030C_A
C5_01010W_A
C3_03400C_A
CR_02130W_A
C1_10180C_A
C1_13310W_A
C2_03680W_A

PDE2
WSC2
WSC2
WSC4
MNN4
Mnn10
SCW10
VTI1
ECM4
ECM21
ECM25
PEP4

Filamentation, Cell Wall Stress
Biofilm ECM, Pathogenesis
Filamentation, Adhesion, Cell Wall Organization
Cell Wall Stress, Cell Wall Organization
Cell Wall Stress
Cell Wall Stress
Cell Wall Biogensis and Stress
Cell Wall Biogensis
Cell Wall Biogensis and Stress, Filamentation, Adhesion, Pathogensis
Cell Wall Stress
Golgi to Vacuole Transport
Core Stress Response, Filamentation
Endocytosis
Filamentation
Phenotypic Switching

Filamentation
Nitrogen Stress, Filamentation
Unknown (Cell Cycle in S. cerevisiae)
Filamentation, Adenine Biosynthesis
Cell Wall Biogensis and Stress, Pathogenesis
Cell Wall Biogensis and Stress, Filamentation, Pathogenesis
Cell Wall Biogensis and Stress, Nitrogen Stress, Filamentation
Cell Cycle
Cell Adhesion
Filamentation, Phenotypic Switching
Filamentation
Filamentation
Filamentation, Cell Wall Stress, Oxidative Stress, Cell
Cell Adhesion, pH Response
Oxidative Stress
Oxidative Stress
Filamentation, Pathogenesis
Filamentation
Filamentation
Filamentation, pH Response
Filamentation, Cell Adhesion
Filamentation
Mating
Filamentation
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HMS1
HMS1
Filamentation
C5_00670C_A
GLN3
GLN3
Nitrogen Stress, Filamentation
C5_04280C_A
C5_04410C_A
C5_04410C_A
AZF1
Unknown (Cell Cycle in S. cerevisiae)
GRF10
C5_05080W_A
PHO2
Filamentation, Adenine Biosynthesis
ZCF21
C4_00760W_A
LYS14
Cell Wall Biogensis and Stress, Pathogenesis
CAS5
C4_01190W_A
MOT3
Cell Wall Biogensis and Stress, Filamentation, Pathogenesis
CWT1
RDS2
Cell Wall Biogensis and Stress, Nitrogen Stress, Filamentation
CR_05530C_A
Table
cell
wall proteins resistant to E. faecalis
MBP1 5.2: Homozygous
C3_04110C_A deletion
MBP1mutants in
Cell
Cycle
TRY4
C3_05050W_A
ADR1
Cell Adhesion
WOR2
C3_05170W_A
UME6
Filamentation, Phenotypic Switching
supernatant.
C2_05640W_A
C2_05640W_A
BAS1
Filamentation
STP4
C2_03220C_A
STP3
Filamentation
SKO1
C1_03770W_A
SKO1
Filamentation, Cell Wall Stress, Oxidative Stress, Cell
CR_07060C_A deletion
CRZ1
Adhesion,
pH Response
C.CRZ2
albicans homozygous
mutantsCellwere
screened
for resistance to E. faecalis
C1_05750C_A
C1_05750C_A
ECM5
Oxidative Stress
MSN4
C1_08940C_A
MSN2
Oxidative Stress
supernatant
biofilm
inhibition. Biofilms
were grown
in YNBAS for 24 hours and biofilm biomass
SSN6
C3_07020W_A
CYC8
Filamentation, Pathogenesis
FCR1
C3_06850W_A
CAT8
Filamentation
NRG1quantified C7_04230W_A
NRG2 redox assay
Filamentation
was
using the resazurin
to compare biofilms grown in the presence or
RIM101
C1_14340C_A
RIM101
Filamentation, pH Response
AAF1
Filamentation, Cell Adhesion
absence
of WTC3_06470W_A
E. faecalis supernatant.
CPH2
C6_00280W_A
HMS1
Filamentation
KAR4
CR_02330C_A
KAR4
Mating
RAP1
C2_10080W_A
RAP1
Filamentation
Gene

Systematic Name

S. cerevisiae
Ortholog

Function

PGA26
PGA7
PDE2
WSC1
WSC2
WSC4
MNN4-4
MNN10
MP65
CCW14
VTI1
ECM4
ECM21
ECM25
SAP98

C1_05760C_A
C4_00120W_A
C1_02840W_A
C3_04250W_A
C6_02670C_A
C1_14360C_A
C6_02830W_A
C4_00310C_A
C2_10030C_A
C5_01010W_A
C3_03400C_A
CR_02130W_A
C1_10180C_A
C1_13310W_A
C2_03680W_A

PDE2
WSC2
WSC2
WSC4
MNN4
Mnn10
SCW10
VTI1
ECM4
ECM21
ECM25
PEP4

Filamentation, Cell Wall Stress
Biofilm ECM, Pathogenesis
Filamentation, Adhesion, Cell Wall Organization
Cell Wall Stress, Cell Wall Organization
Cell Wall Stress
Cell Wall Stress
Cell Wall Biogensis and Stress
Cell Wall Biogensis
Cell Wall Biogensis and Stress, Filamentation, Adhesion, Pathogensis
Cell Wall Stress
Golgi to Vacuole Transport
Core Stress Response, Filamentation
Endocytosis
Filamentation
Phenotypic Switching
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perturbation of this signal cascade (408). Interestingly, deletion of negative regulators of the
signal pathway, NRG1 and PDE1, conferred resistance to E. faecalis, demonstrating the
importance of the Ras1-cAMP-PKA signal pathway regulation of hyphal morphogenesis in
response to E. faecalis (Fig 5.1A). This suggests that E. faecalis-mediated inhibition requires
repressors of hyphal morphogenesis that are most likely induced during inhibition. Nrg1 is
essential for the hyphal to yeast transition during the dispersal stage of biofilm development
and negatively regulates the biofilm transcriptional network (155). Pde2 is a high affinity cyclic
nucleotide phosphodiesterase that moderates signaling by cAMP in the Ras1-cAMP-PKA
signal pathway (50, 397, 400).
The stress response MAPK network consists of three terminal MAPKs, Hog1, Mkc1 and
Cek1, that are phosphorylated as a result of membrane sensors signaling in responses to
environmental stress, such as surface stress (48, 399). Deletion of transcription factors
regulated by the MAPK network, CAS5, SKO1, and FCR1, conferred resistance to E. faecalis,
demonstrating a possible role of the MAPK pathway during inhibition hyphal morphogenesis by
E. faecalis (Fig 5.1B). Furthermore, deletion of the poorly understood cell wall integrity sensors,
WSC1, WSC2, and WSC4, decreased sensitivity to E. faecalis supernatant (Fig. 5.1B). At the
center of the MAPK network is Hog1-MAPK, which at basal concentrations represses Cek1 and
controls phosphorylation of Mkc1 (5, 409). Phosphorylated Hog1 acts a repressor of hyphal
morphogenesis independently of Efg1 and Cph1 by regulating Sko1-Ssn6-Tup1 mediated
repression. Thus, I hypothesized that the Hog1-MAPK stress response pathway is activated in
C. albicans due to E. faecalis-mediated perturbation of the cell wall and membrane. Deletion of
HOG1 resulted in decreased sensitivity to E. faecalis supernatant (Fig 5.2). Taken together
these results suggest that the stress response MAPK network is activated in response to E.
faecalis-mediated stress.
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Figure 5.1: Deletion of hyphal morphogenesis and cell wall stress genes confers
resistance to E. faecalis supernatant.
C. albicans homozygous deletion mutants were screened for resistance to E. faecalis
supernatant biofilm inhibition. Biofilm biomass was quantified using the resazurin redox assay
comparing no treatment biofilms (blue) to supernatant treated biofilms (orange). (A) Deletion of
genes involved in repression of the Ras1-cAMP pathway resulted in decreased sensitivity to E.
faecalis supernatant. (B) Deletion of genes involved in cell wall stress resulted in decreased
sensitivity to E. faecalis supernatant. Statistically significant differences relative to treatment
with the WT supernatant were calculated using a Student’s t-test, and are indicated by
asterisks (**, p<0.007; *, p<0.04).
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Figure 5.2: Deletion of the central stress response MAPK, HOG1, decreased C. albicans
sensitivity to E. faecalis supernatant.
Treatment with E. faecalis WT supernatant did not decrease biofilm biomass of a HOG1
homozygous deletion mutant and complementation of the WT HOG1 restored sensitivity. was
resistance to E. faecalis supernatant biofilm inhibition. Biofilm biomass was quantified using the
resazurin redox assay comparing no treatment biofilms (blue) to supernatant treated biofilms
(orange). Statistically significant differences relative to treatment with the WT supernatant were
calculated using a Student’s t-test, and are indicated by asterisks (**, p<0.006; *, p<0.03).
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Host relevant environmental stresses impact on EntV activity
Functional stress response is important for C. albicans survival by initiating adaptation
to changes in environmental conditions (401). Induction of MAPK stress response pathways
has been observed in C. albicans in response to various external factors that lead to inhibition
of hyphal morphogenesis and biofilm formation. Thus, I considered whether sEntV might
synergize with host-relevant stresses, including oxidative, nitrosative, cell wall, and cell
membrane stresses. The addition of sEntV68 did not affect susceptibility to any of these
stresses, reinforcing the idea that it has a novel mechanism of action (Fig 5.3). These results
do not correspond with our previous observations in the in vitro biofilm model. There are some
plausible explanations: (1) there is no stress response, (2) the stress response is specific to
biofilm growth (e.g. adhesion), and/or (3) the stress growth conditions impedes the activity of
EntV68 (e.g. cell surface remodeling). This remains to be fully elucidated and will need to be
further examined.

EntV activity on C. albicans in different growth conditions
To better understand the sEntV68 mechanism of action, I considered whether EntV
might inhibit biofilm formation as a result of a general inhibition of fungal growth. To address
this, I grew C. albicans in the presence of increasing concentrations of sEntV68 and found no
reduction in growth as high as 10 µM, 30,000-fold higher than the in vitro biofilm inhibitory
concentration (Fig 5.4). Although sEntV68 was very effective at inhibiting biofilm formation in
artificial saliva medium (YNBAS), I questioned the efficacy of sEntV68 in stronger hyphal
inducing conditions. As illustrated in Figure 5.5, sEntV68 is highly active in a variety of media
conditions, including fetal bovine serum (FBS), which is a robust hyphal inducer (Fig. 5.5)

Role of cell wall composition in response to E. faecalis mediated inhibition
While many of the genes identified in the homozygous deletion mutants screen have
hyper-filamentous phenotypes, deletion of ZCF21 conferred resistance to E. faecalis

102

Medium Only
DMSO
CFW
CFW + DMSO
CFW + EntV68
EntV68

1.0

B.

1.5

1.0

0.5

0

1.5

5

10
Time (Hours)

Medium Only
DMSO
H 2O 2
H2O2 + DMSO
H2O2 + EntV68
EntV68

Absorbance (OD600)

C.

0.5

1.0

0
15

D.

10
Time (Hours)

15

Medium Only
DMSO
Menadione
Menadione + DMSO
Menadione + EntV68
EntV68

5

10
Time (Hours)

Medium Only
DMSO
NaCl
NaCl + DMSO
NaCl + EntV68
EntV68

1.0

0
15

F.

0

1.5

1.0

0.5

5

10
Time (Hours)

15

Medium Only
DMSO
Sorbitol
Sorbitol + DMSO
Sorbitol + EntV68
EntV68

Absorbance (OD600)

0

1.5

0

5

0.5

Absorbance (OD600)

E.

1.5

1.0

0.5

0

0

Absorbance (OD600)

0

Medium Only
DMSO
SDS
SDS + DMSO
SDS + EntV68
EntV68

Absorbance (OD600)

1.5
Absorbance (OD600)

A.

0.5

0

5

10
Time (Hours)

0
15

0

5

10
Time (Hours)

15

Figure 5.3: Impact of host relevant stresses on sEntV68 activity.
C. albicans (SC5314) was grown for 15 hours in YPD at 30° C with sEntV68 (100 nM) in
different stress conditions: cell wall stress (A) calcofluor white (100 μg/ml) and (B) SDS (10%);
cell membrane stress (C) sorbitol (1 M) and (D) Sodium Chloride (1 M); oxidative stress (E)
hydrogen peroxide (5 mM) and (F) menadione (100 μM)

in a 96 well plate. OD600 was

measured every two minutes in a microplate reader.
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Figure 5.4: sEntV68 activity on planktonic C. albicans yeast cells.
C. albicans was grown at 30°C in YPD for 15 hours with shaking in a 96 well plate with
increasing concentrations of sEntV68. Growth of was quantified by measuring absorbance
(OD600) every two minutes in a microplate reader (BioTek).
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Figure 5.5:. sEntV68 inhibitory activity in different media types.
C. albicans (HWP1p::GFP) biofilms grown for 24 hours at 37°C in YNBAS, RPMI, Spider, or
YPD with 10% fetal bovine serum with 0.01% DMSO (blue) or 100 nM sEntV (orange). Hyphal
morphogenesis was quantified by measuring GFP fluorescence as a ratio to the OD 600 for three
separate experiments and statically significant differences were calculated using a Student’s ttest (*p<0.01).
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supernatant in a hyper-filamentous independent manner (Fig. 5.6, Table 2.1) (9). Zcf21p
negatively regulates expression of genes that encode cell surface proteins important for C.
albicans virulence (410). Bohm et al. (280), found that ZCF21 regulates cell wall structure and
composition, including proteins and carbohydrates in the cell wall. Furthermore, the
homozygous ZCF21 deletion mutant had decreased sensitivity to sEnV68, suggesting that
deletion of ZCF21 causes changes in the cell wall structure and composition preventing
sEntV68 inhibition.

EntV localization in C. albicans
Analysis of the primary and predicted secondary structure (Chapter 4) indicate EntV68
has similar physicochemical properties to human antimicrobial peptides active against C.
albicans that elicit a surface stress response that is initiated via interactions with the cell wall
and cell wall associated proteins (280, 295, 302). Similar to EntV68, the cationic properties of
LL-37, β-d3, and Hst-5 are thought to promote interactions with the anionic microbial surface
and the amphipathic structures allow the peptides to interact with microbial membranes (411).
Thus, I hypothesized that EntV68 may interact with the cell surface of C. albicans in a similar
fashion. As demonstrated in Figure 5.7, sEntV68 with a C-terminal FITC tag localized to the cell
surface of C. albicans yeast and hyphal cells, suggesting that the EntV68 mechanism of action
is cell surface dependent.

EntV68 activity target spectrum
Since sEntV68 is efficacious in both in vitro and in vivo conditions and has therapeutic
potential, I tested the efficacy of sEntV68 against clinical isolates of C. albicans and other
pathogenic Candida species to gain further insight into the spectrum of fungal targets and
mechanism of action. I found that sEntV68 significantly reduced biofilm formation of clinical
isolates, including azole resistant strains (Fig. 5.8A) (395, 412). Furthermore, sEntV68 was also
active against biofilms formed by other C. glabrata, C. tropicalis, and C. parapsilosis (Fig..
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Figure 5.6: Deletion of ZCF21 decreased C. albicans sensitivity to E. faecalis supernatant
and sEntV68.
C. albicans biofilms grown for 24 hours in YNBAS at 37°C for 24 hours with (A) sterile medium
(blue) or supernatant (orange) and (B) 0.01% DMSO (blue) or 100 nM sEntV (orange). Biofilm
biomass was quantified using the resazurin redox assay. Statistically significant differences
relative to treated and control biofilms were calculated using a Student’s t-test, and are
indicated by asterisks (**, p<0.007).
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Figure 5.7: Localization patterns of sEntV68 on the surface of C. albicans.
68
sEntV
Planktonic cultures of C. albicans expressing
constitutive
mCherry were incubated in YNBAS

sEntV68-FITC

with 100nM sEntV68-FITC at (A) 30°C for hour, (B) 37°C for 1 hour, or (C) 37°C for 1 hour
without sEntV68-FITC to allow for germ-tube formation followed by 1 hour incubation with
sEntV68-FITC. Localization of sEntV68-FITC was observed by fluorescence microscopy
(Olympus IX81) using slidebook 6 (3i, Intelligent Imaging Innovations). (D) Biofilms were grown
with increasing concentrations of sEntV68 or sEntV68-FITC and the IC50 calculated at 0.3 nM
and 0.5 nM, respectively.
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Figure 5.8:. sEntV68 target spectrum.
(A) sEntV68 inhibitory activity against clinical isolates of C. albicans. Stain names in red are
resistant clinical isolates that resistant to azoles. C. albicans biofilms grown for 24 hours in
YNBAS at 37°C for 24 hours with 0.01% DMSO (blue) or 100 nM sEntV (orange). (B) sEntV68
inhibitory activity against different Candida species. C. albicans, C. tropicalis, C. parapsilosis
and C. glabrata biofilms grown for 24 hours in RPMI at 37°C for 24 hours with 0.01% DMSO
(blue) or 100 nM sEntV (orange). Biofilm density was quantified by measuring resazurin
fluorescence for three separate experiments and statically significant differences were
calculated using a Student’s t-test (*, p<0.05; **, p<0.01).
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5.8B). Taken together these results suggest that EntV68 is a specific inhibitor of hyphal and
biofilm growth with a broad spectrum of activity against C. albicans and Candida spp .

Discussion:
The mechanism by which EntV inhibits C. albicans hyphal growth and biofilm formation
is unresolved. However, homozygous deletion mutants resistant to E. faecalis supernatant
revealed that hyphal morphogenesis and surface stress response functions are important for
the mechanism of action. Localization of the fluorescent peptide suggests a cell surface (wall or
membrane) localization, and I have no evidence that it exerts any cytotoxic or lytic stress
against C. albicans. Quite the contrary: while sub-nanomolar concentrations of EntV are
sufficient to inhibit biofilms, concentrations 10,000-fold higher do not reduce fungal growth,
even in the presence of concurrent stresses that damage the cell wall or membrane.
Plausible mechanisms include EntV interfering with a cell surface receptor or a hyphal
inducing factor or blocking cell-cell or cell-substrate binding mediated by one or more of the C.
albicans adhesins. Several of the homozygous deletion mutants, including ZCF21, disrupt the
cell wall composition that could lead to masking of a binding target protein or component of the
cell wall or membrane. Disruption of the cell wall composition and structure can also impair
biofilm development and is often mediated by cell stress response (20). Genetic and
biochemical studies will be necessary to elucidate the mechanism of action.
Biofilms provide protection to microbes by production of the ECM that encases the
microbes protecting them from the immune response and antibiotics (39). Thus, biofilm related
infections present many clinical challenges by complicating treatment strategies (80). With the
limited antifungals available fungal infections are difficult to treat. Furthermore, resistance to
traditional antifungals is an increasing concern. Traditional antifungals interfere with essential
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biological processes to kill or inhibit fungal growth and can have off target effects that can be
toxic to the patient (91, 413). To overcome these challenges targeting virulence traits rather
than essential fungal processes has recently been proposed to alleviate the selection pressure
for resistance (410).
Moreover, targeting virulence factors will keep opportunistic pathogens in check rather
than disrupting the entire mycoflora with antifungal treatment. One of the most abundant fungal
species found in humans, C. albicans does not have any known environmental reservoir (410).
This suggests that C. albicans has a profound association with humans and has coevolved
considerably with the human host. Additionally, the majority of healthy individuals are colonized
with C. albicans as part of the normal GI microflora (414, 415). That said, the beneficial effects
of C. albicans colonization cannot be excluded, and might provide another rationale for why the
use of an alternative antifungal could be advantageous. Collectively, our work suggests that
EntV is a promising alternative therapeutic that targets hyphal morphogenesis and biofilm
development with a spectrum of activity against clinical isolates and other pathogenic Candida
spp.
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Chapter 6:

Discussion and Perspectives
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Summary:
E. faecalis and C. albicans occupy overlapping niches as ubiquitous parts of the
gastrointestinal and oral microbiome. As opportunistic pathogens these species are also
amongst the most important and problematic nosocomial pathogens. I have observed
antagonistic interactions between these two species, where virulence of both microbes is
attenuated in the C. elegans infection model. Inhibition of C. albicans hyphal morphogenesis
was a striking phenotype observed in this infection model. Inhibition of hyphal morphogenesis
was also obtained by addition of E. faecalis spent supernatant in the C. elegans infection model
and in vitro biofilm model (115).
I have identified the inhibitory factor as an E. faecalis bacteriocin, EntV, which was
necessary and sufficient for the reduction of C. albicans virulence and biofilm formation via its
inhibition of hyphal morphogenesis. As illustrated in Figure 6.1, I have demonstrated that the
EntV propeptide is post-translational modified for maximum activity. The synthetic version of
the mature 68-amino acid peptide inhibited biofilm development in multiple media conditions
and disrupted pre-formed biofilms. sEntV68 was protective in different fungal infection models at
nanomolar or lower concentrations.
First, nematodes treated with the peptide at 0.1 nM are completely resistant to killing by
C. albicans (data not shown see (303)). sEntV68 was protective in the macrophage infection
model and works in synergy with the macrophages increasing their antifungal activity. Finally,
EntV68 reduced epithelial invasion, inflammation, and fungal burden in a murine model of
oropharyngeal candidiasis. Hyphal morphogenesis was inhibited in all three models. However,
EntV68 had no effect on C. albicans viability, even in the presence of significant host-mimicking
stresses. These findings demonstrate the therapeutic potential of EntV as a novel antifungal
agent that targets virulence rather than viability, which is important considering the increase in
resistance to traditional antifungals.
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Figure 6.1: Summary of EntV processing and activity.
The inhibitory activity produced by E. faecalis was first characterized using an in vitro biofilm.
EntV was identified as the inhibitory factor produced by E. faecalis and is proteolytically
cleaved produce the active peptide that inhibits morphogenesis in the biofilm assay, murine
macrophage infection model, and murine OPC model. Inhibition of hyphal morphogenesis
reduced biofilm formation, and attenuated virulence of C. albicans during infection.

114

Furthermore, I demonstrated the physiochemical properties of EntV and the post-translational
modifications that are necessary for activity. Upon assessment of the other closely related
class IIIb bacteriocins from different bacteria, I observed prominent similarities in possible posttranslational

modifications

and

predicted

secondary

structures.

This

preliminary

characterization of the class IIIb bacteriocins provides useful insight for the future design of
EntV-based therapeutic strategies and demonstrates the importance of the class IIIb
bacteriocins for these Gram-positive bacteria and their conceivable role in fungal-bacterial
interactions.
To understand how E. faecalis inhibits C. albicans biofilms and hyphal morphogenesis, I
identified C. albicans genes that confer decreased sensitivity to E. faecalis inhibitory activity
during biofilm development. Screens of homozygous deletion mutants revealed that deletion of
genes involved in regulation of hyphal morphogenesis, cell wall stress, and cell wall
architecture decreased sensitivity to E. faecalis supernatant. This suggests that EntV may
target processes involved in these functions, since perturbation decreases efficacy of E.
faecalis inhibitory activity. Furthermore, sEntV68 localized to the cell surface of both yeast and
hyphal cells. As illustrated in Figure 6.2, I have demonstrated that modification of C. albicans
cell wall components or hyperfilamentation produces decreased sensitivity to E. faecalis
mediated inhibition of biofilm development. Thus, I hypothesize that EntV targets the cell
surface, which disrupts cell surface function(s) that are necessary for hyphal morphogenesis
and biofilm development, most likely a function that is linked between these important virulence
determinants. I also examined the target spectrum of sEntV68 and found that clinical isolates of
C. albicans, including azole restraint strains, and other pathogenic Candida spp. are sensitive
to sEntV68. This suggests that the mechanism of action targets a common function amongst
these different strains and species. In total, these data demonstrate the therapeutic potential of
sEntV68 or similar compounds for development of therapeutic strategies that target hyphal
morphogenesis and biofilm development.
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Figure 6.2: Summary of homozygous deletion mutant functions.
Of the 263 mutant screened 39 were less sensitive to E. faecalis supernatant. Collectively,
most of these mutants have functions associated with cell wall composition and/or hyphal
morphogenesis. Many of the cell wall mutants have functions associated with cell wall stress
and are important for maintenance of cell wall integrity and architecture and deletion of these
genes leads to cell surface remodeling. Of the 24 transcription factors, many have functions
associated with regulating hyphal morphogenesis and many were hyperfilamentous as result of
upregulation of hyphal specific genes.
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C. albicans-E. faecalis interactions during commensalism and pathogenesis
Given the epidemiology of E. faecalis and C. albicans infections, their overlapping
niches, and our current findings, it is plausible that these species have synergism during
commensal colonization. As I observed previously in the nematode infection model, virulence
of both microbes was attenuated, suggesting that their interactions promote non-pathogenic
association with the host (115). Previous studies also demonstrate synergism during
commensal colonization. Mason et al. (416) demonstrated that E. faecalis becomes more
abundant after antibiotic treatment in mice colonized with C. albicans in both the stomach and
the cecum. Considering C. albicans does not naturally colonize the GI tract of mice and
antibiotic treatment is necessary to establish C. albicans colonization (417); it is plausible that
the increase in E. faecalis also promotes commensal colonization of C. albicans (418).
On the other hand, during infection C. albicans and E. faecalis are commonly coisolated in a variety of different types and severity of infections (109, 157, 159, 182). One
common theme among these co-infections is the status of the host changes due to immune
dysfunction and/or disruption of anatomical barriers, suggesting that a complex relation exists
between E. faecalis and C. albicans that is dependent on the host. Consistent with clinical
reports, Carlson et al. (151) found that co-infection with E. faecalis and C. albicans enhanced
dissemination of E. faecalis pathogenesis in a murine intraperitoneal infection model.
Considering these results and the clinical indices of E. faecalis and C. albicans co-infections, it
is plausible that when immune dysfunction, loss of anatomical barriers, and/or disruption of the
microflora occurs E. faecalis is able to hitch a ride, so to speak, with C. albicans during
disseminated infection. A similar occurrence has been demonstrated in C. albicans and P.
aeruginosa, where in vitro antagonism is observed and clinical co-infections are more severe
(Chapter 1).
In view of our results, current literature, and clinical reports, Figure 6.3 illustrates our
predicted model of the complex relationship that exists between E. faecalis and C. albicans. In
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the presence of a healthy host both microbes are able to colonize as commensal microflora.
However, with a change in the host status both microbes can become pathogenic (8, 366).
During antibiotic treatment, E. faecalis is capable of surviving because of their genomic
plasticity and ability to take up resistance genes and virulence traits via conjugation [436].
Thus, E. faecalis is capable of surviving with antibiotic treatment along with C. albicans.
However, with antibiotic treatment the population of E. faecalis is likely reduced, repressing Fsr
and in turn EntV production (356). Under these conditions, C. albicans is able to grow,
proliferate, and form hyphae. If the host has a compromised immune response, C. albicans is
able to disseminate and survive and possibly allow the remaining E. faecalis a mode of
dissemination (8). In the case of disrupted anatomical barriers, such as seen in intraperitoneal
infections, both E. faecalis and C. albicans are able to survive in the hostile environment of the
intraperitoneal cavity allowing further dissemination of both microbes (183, 184). To
substantiate this model many more questions must be addressed, which will be discussed
subsequently.

Role of E. faecalis bacteriocins in the host environment
Many of the bacteriocins produced by E. faecalis are found on plasmids and vary from
strain to strain. Different bacteriocins-producing E. faecalis strains have been isolated from a
broad range of sources, from commensal strains found in food and feces to pathogenic strains
found in different types of infections. Interestingly, some bacteriocins produced by E. faecium
are also produced by E. faecalis commensal and pathogenic strains (419). Although the
majority of bacteriocins produced by E. faecalis target closely related Gram-positive bacteria
and are thought to be important for competition with other bacteria, cytolysin is the exception
because it targets other bacteria and eukaryotic cells. Cytolysin production was first observed
in clinical isolates and conferred increased hemolysis (420). Furthermore, many E. faecalis
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strains produce multiple bacteriocins and many of the same bacteriocins are produced in
strains isolated from extremely different environments, indicating that these bacteriocins are not

Figure 6.3: Model of C. albicans-E. Faecalis interactions in the GI tract.
In the healthy host C. albicans and E. faecalis have commensal like association with the host.
There are abundant populations of E. faecalis. Thus, the Fsr system has been stimulated by
accumulation of the QS molecule GABP and active EntV is being produced in sufficient
concentrations to inhibit hyphal morphogenesis. In the unhealthy host who has compromised
immune function, disrupted microflora, and/or loss of anatomical barriers C. albicans is able to
penetrate the epithelial layer allowing E. faecalis to escape the intestinal lumen. As the status
of the host deteriorates both C. albicans and E. faecalis become opportunistic pathogens.
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niche specific and rather have a general advantage in any niche [440].

Role of EntV in the host environment
EntV is found in all sequenced E. faecalis strains, indicating that entV function is
important for E. faecalis survival and is not niche specific. As mentioned previously, entV is
regulated by the Fsr two-component system. The Fsr system is regulated by accumulation of
the QS molecule GABP, suggesting that production and function of EntV is important when E.
faecalis populations are at higher concentrations. In an environment such as the human GI
tract E. faecalis populations can be 107 CFU/μg. In this environment, competition with
neighboring bacterial species that are closely related and likely require similar nutrients is
important [441]. Production of a bacteriocin such as EntV could be advantageous.
Moreover, production of EntV in the GI tract could also be beneficial during commensal
colonization with C. albicans. As demonstrated in our current and previous findings, EntV
promotes commensal-like association with the host in C. albicans by inhibition of hyphal
morphogenesis (115, 303). Although hyphal cells are considered the invasive and more
pathogenic form of C. albicans, there is much debate on this topic (47). Some literature
suggests that the yeast form is the commensal, noninvasive morphology and the hyphal form is
the invasive pathogenic morphology. This is an over simplification. During invasive infection
both morphologies are necessary and the dominance of one morphology over the other
depends on the infected organ (421). Moreover, it is unclear what morphology predominates
during commensal colonization. Kumamoto et al. (422, 423), reported the expression of hyphalassociated genes during commensal colonization in a murine GI colonization model, despite
the fact that C. albicans was found predominately in the yeast form. That said, C. albicans
mutant strains locked in either the yeast form or hyphal form have attenuated virulence,
suggesting the transition between the two states is dynamic and necessary for maximum
virulence (361, 424, 425). Thus, it is plausible that production of EntV during commensal
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colonization with C. albicans is capable of inhibiting hyphal morphogenesis and promoting
commensalism. Furthermore, yeast cells are far less immunogenic and are not recognized by
phagocytes, while hyphal cell are much more immunostimulatory (426-428). Thus, controlling
hyphal morphogenesis could benefit the microflora including E. faecalis by keeping the immune
response restrained.
The class IIIb bacteriocins, including EntV, are unusual compared to other classes of
bacteriocins. The majority of propeptides are small where as the class IIIb bacteriocins are
large and only about half of the propeptide is necessary for activity (Chapter 4). Most
bacteriocins have an immunity protein that is encoded on a neighboring gene or with the same
operon. This is the case with the class IIIb bacteriocins, except for EntV where the immunity
protein has not been identified. Dundar et al. (245) attempted to identify the immunity protein to
no avail. A translationally coupled gene was identified by bioinformatics as a candidate
immunity factor (ef1097b). However, deletion of ef1097b had no effect on E. faecalis sensitivity
to EntV. I considered whether the N-terminal portion of the propeptide might be the immunity
factor. Nevertheless, ΔentV is not sensitive to sEntV68 (data not shown), suggesting that
intrinsic immunity to sEntV68 occurs by another mechanism or gene and remains to be
elucidated.
Gene expression data demonstrated that entV expression is the same in the pathogenic
strain E. faecalis V583 as the commensal strain E. faecalis OG1RF, suggesting that EntV is
expressed in all E. faecalis strains in a similar manner (356, 357). Furthermore, Bourgogne et
al. (356), identified a FsrA binding consensus sequence that is present in all strains of
sequenced E. faecalis. In addition to the Fsr operons, gelE and sprE, and entV, ef1352 that
encodes a putative magnesium-translocating P-type ATPase was unregulated in response to
GABP stimulation (Fsr activation) (357). Nonetheless, ef1352 does not have an FsrA binding
consensus sequence, suggesting that ef1352 is not directly regulated by the Fsr system and
perhaps is induced by EntV causing ion leakage. This remains to be elucidated and would be in
stark contrast to the immunity factors of other class IIIb bacteriocins (243, 358, 429).
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The EntV mechanism of action against bacteria has not been fully elucidated, aside
from the non-lytic manner of bactericidal activity. However, other class IIIb bacteriocins have
been studied in much more detail. DysA (dysgalacticin) is produced by Streptococcus
dysgalactiae subsp. equisimilis and the mechanism of action for DysA has been investigated in
some detail. Swe et al. (394, 429) found that DysA has a non-lytic mode of action that is
bactericidal, inhibited glucose fermentation by targeting glucose/mannose-PTS, increased
membrane permeability that mediated intracellular ion leakage. Given the similarity in
secondary structure I hypothesis that EntV has a similar mode of action that is mediated by
insertion into the membrane of target bacteria (Fig 6.4). AMPs with similar physiochemical
properties as EntV can target both fungi and bacteria (295, 302, 430). Thus, it is conceivable
that EntV also interacts with the membrane of C. albicans, albeit to a lesser degree given the
complex structure of the cell wall of C. albicans and differences in lipid composition compared
to bacteria (13, 431). Human AMPs that are active against C. albicans, Hst-5, LL-37, hBD-3,
are also active against bacteria, and inhibit hyphal morphogenesis and biofilm adhesion at sublethal concentrations in C. albicans. Considering this it is plausible that only low concentrations
of EntV are able to insert into the membrane of C. albicans causing membrane stress that
mediates inhibition of hyphal morphogenesis and biofilm development. However, given the lack
of synergism of EntV with known membrane and cell wall stressors, this may be an over
simplification of a very complex interaction.

Therapeutic potential of bacteriocins and future application
As previously mentioned, application of bacteriocins as therapeutics for human use has been
limited to probiotics and application in food as preservatives (Introduction). Reports of in vivo
use of bacteriocins have also focused on the use of probiotic bacteria that express and
potentially secrete the bacteriocins in the gastrointestinal tract (432). Although the use of
bacteriocin-producing probiotics may be as beneficial as prophylactics, application of purified
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Figure 6.4: Predicted membrane topology of active EntV.
The two-amphipathic helices of EntV are predicated to insert into the cytoplasmic membrane of
susceptible targets. The disulfide bridge is predicted to remain on the outer leaflet of the
membrane. Membrane topology was predicted using PHDhtm transmembrane helices
predictions (NPS), where the EntV amino acid sequence is compared and aligned to similar
sequences to obtain a more accurate predicted membrane topology (310).
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bacteriocins would be superior at countering established infections. Application of purified nisin
has been successful, but has been limited to application in food (244). One of the greatest
impediments in the therapeutic application of purified bacteriocins is the stability of the
bacteriocin in the host environment (433). Engineering bacteriocins to increase stability and
potency will overcome this problem. To design bacteriocins with increased stability and potency
an understanding of bacteriocins that are effective in vivo is necessary. The stability and target
spectrum of EntV have not been extensively studied, thus in the event that an enhanced
version would be ideal strategies for modification of class II bacteriocins can be used for EntV.
Another, important factor to consider is that the size of EntV is twice as large as the class II
bacteriocins, which have been extensively used and tested and are more cost effective
treatment strategies.
The class IIa bacteriocins structure-function relationship has been extensively studied
and the in vivo efficacy has been examined. Dabour et al. (434) found that intra-gastric
application of pediocin PA-1, produced by Pediococcus acidilactici, was efficacious in mice with
GI infections of Listeria monocytogenes. Infected mice where given repeat doses (250 μg/ day)
of purified pediocin PA-1 for three days, which resulted in up to 2-log reductions in L.
monocytogenes in feces and translocation into the liver and spleen was slowed. Furthermore,
L. monocytogenes completely disappeared in the liver and spleen within six days of treatment.
Another class IIa bacteriocins that has been studied in vivo is piscicolin 126 from
Carnobacterium piscicola. Ingham et al. (435) found that after tail vein injection into mice
piscicolin 126 retain activity against L. monocytogenes. Mice were infected intravenously with
L. monocytogenes followed by intravenous treatment with purified piscicolin 126, which
significantly reduced L. monocytogenes in the liver and spleen reducing clinical signs of
disease. Likewise, Rihakova et al. (436) demonstrated that the divercin RV41 bacteriocin
produced by Carnobacterium divergens significantly reduced L. monocytogenes during
invasive infection. The efficacy of structural variants with mutation in different amino acids was
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also tested and while all retained activity against L. monocytogenes the level of potency varied,
demonstrating that certain amino acids are required for activity.
Unlike traditional antibiotics bacteriocins are confronted with challenges related to their
structure as peptides. The structure-function relationships and in vivo efficacy observations can
provide insight to determine engineering methods to enhance stability and potency of
bacteriocins, such as EntV. Some commonly used methods to increase stability are: (1)
introduction of additional disulfide bridges (437, 438), (2) amino acid substitutions including
incorporation of D-amino acids (439, 440) (3) encapsulation of bacteriocins in liposomes (441443). The class IIa bacteriocins have one or more disulfide bridges that are important for
activity and target specificity (242). Fimland et al. (437) found that addition of a C-terminal
disulfide bridge into sakacin P produced by Lactobacillus sakei, which only has an N-terminal
disulfide bridge, broadened the target spectrum, increased potency and decreased temperature
sensitivity. To reduce proteolytic cleavage of bacteriocins by proteases found in the
gastrointestinal tract, O’Shea et al. (439) altered trypsin recognition sites in salivaricin P, a
class IIb bacteriocin produced by Lactobacillus salivarius. Antimicrobial activity was retained
with these alterations and salivaricin P variants were resistant to trypsin digestion. In the event
that modification of the bacteriocin disrupts activity, encapsulation of the bacteriocin can be
preserving. Were et al. (443) observed that encapsulation of nisin and lysozyme increased
efficacy of nisin against L. monocytogenes by stabilizing the bacteriocin activity and structure.
To enhance the potency of bacteriocins the physiochemical properties that contribute to
the mode of action must be considered. As demonstrated in Chapter 4, active EntV is
amphipathic and has a net positive charge (~9.84). Proteolytic cleavage of the propeptide
increased activity against C. albicans (Chapter 3). This corresponds with enhancement of the
positive net charge that promotes the initial electrostatic interaction with the target cell.
Likewise, Kazazic et al. (444) demonstrated that addition of positively charged amino acids at
specific residues enhanced activity of sakacin P by increasing cell binding.
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There are different methods that have been used previously with success to develop
engineered bacteriocins (433). Rational substitution of amino acids is one such method that
depends on the structure-function relationship of the bacteriocins. Use of error-prone PCR to
randomly generate mutants is another approach. However, greater modifications are usually
required to improve bacteriocin activity, as bacteriocins have evolved to be as effective as
possible (242, 445). An alternative approach that allows for major modification is creating
chimeras of with different bacteriocins from the same class to create a DNA-shuffling library to
create hybrids with increased activity and broadened spectrum targets (445).
Traditional antimicrobial therapies often have broader-spectrum of activity than
bacteriocins, thus having a greater impact on the commensal microflora. Often keeping
opportunistic pathogens at bay, the commensal microflora acts a barrier to infection and
disruption of the commensal microflora with antimicrobial treatment is a growing concern. An
advantage over traditional antimicrobials, bacteriocins often have specific microbial targets, and
due to their composition are less likely to be toxic because they are easily broken down into
nontoxic amino acids. Correspondingly, our cytotoxicity assays (Chapter 3) demonstrated that
sEntV68 is not toxic to murine macrophages or Human cervical epithelial cells. Likewise,
Jasniewski et al. (446) found that two class IIa bacteriocins, Cbn BM1 and Cbn B2 produced by
Carnobacterium maltaromaticum, in combination or alone had no cytotoxic effects on human
gastrointestinal cells (Caco-2) at concentration 100-folder than what was required for
antimicrobial activity.

Future perspectives and directions
As mentioned previously, C. albicans biofilms are a growing concern in the clinical
setting. Due to their complex structure, encasement in the ECM, and production of persister
cells traditional antifungals are ineffective at eradicating C. albicans biofilms. In addition there
are currently no biofilm-specific therapeutics used clinically further complicating treatment
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strategies (39). Several chemicals have been identified that specifically target biofilm formation,
while others target hyphal morphogenesis (92, 111, 447). These studies are insightful and
show promise for the development of biofilm specific treatment strategies. Likewise, our
findings demonstrate the possible use of a natural-based peptide for control and treatment of
C. albicans biofilms that has many advantages over the use of other treatment.
Here, I have described very complex and ecologically important interactions between E.
faecalis and C. albicans. As described in Chapter 3, I have identified a bacteriocin, EntV that
has therapeutic potential in different in vitro and in vivo models. Furthermore, I have
characterized EntV activity with respect to post-translational processing that results in
production of a highly active version of EntV. Additionally, I have identified genes that when
deleted decrease C. albicans sensitivity to E. faecalis supernatant and sEntV68. Lastly, I
examined the spectrum of target activity for sEntV68. Although, I have addressed many of the
questions I had when starting this project, there are still many more intriguing questions left to
answer.

Is sEntV68 efficacious in other mammalian infection models with C. albicans?
C. albicans can cause a variety of different infectious, from superficial infections (OPC,
vaginal candidiasis) to systemic infections (endocarditis, candidemia, intraperitoneal infections).
Recall that during invasive infection the yeast-hyphal transition is necessary for maximum
virulence. However, the dominance of one morphology over the other depends on the infected
organ (421). Thus, it would be insightful to assess the efficacy of EntV an invasive infection
model, such as the intravenous tail vein injection model. Considering that other bacteriocins are
effective in invasive bacterial infections, EntV would be expected to decrease dissemination of
C. albicans. Nevertheless, EntV does not have fungicidal activity during planktonic growth so
the effects of EntV may be moderate.
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Given our observation in the C. elegans infection model, where commensal-like
association with C. elegans was observed, I speculate that these species have synergism
during commensal colonization. This could be confirmed using the murine colonization model
(422). Perez et al. (9) screened homozygous transcription factor deletion mutants in both the
murine intestinal colonization and systemic infection models. Eight transcriptional regulators
were identified that have roles in at least one of the models examined. 800 target genes where
identified by genome-wide chromatin immunoprecipitation that are regulated by the eight
transcriptional regulators. Interestingly, many pathogenesis associated genes were upregulated
during commensal colonization suggesting that commensalism and pathogenicity are
genetically intertwined
Addition of EntV to either of these models could change the gene expression profiles or the
specific genes identified.

Is sEntV68 efficacious against other fungal pathogenes not closely related to C.
albicans?
sEntV68 was active against biofilms formed by other C. glabrata, C. tropicalis, and C.
parapsilosis. Although all of these species belong to the Candida genus, only C. tropicalis and
C. parapsilosisi are closely related to C. albicans and are part of the CUG clade that translate
the CUG codon as serine instead of leucine (448). C. glabrata is more closely related to S.
cerevisiae. The Candida genus originally included yeast species that are able to form hyphae
or psuedohyphae and have no observed sexual spores. Although C. albicans remains the
leading of cause of candidiasis, isolation of non-albicans Candida (NAC) species is increasing
in patients. C. glabrata followed by C. parapsilosis and C. tropicalis were the most common
NAC species isolated worldwide in a 10 year retrospective analysis of NAC species infections
(449). Interestingly, EntV has inhibitory activity against all of these species, suggesting the
mechanism of action requires a common feature found in these different species.
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C. albicans, Cryptococcus neoformans and Aspergillus fumigatus are among the most
prevalent fungal pathogens. Resistance to traditional antifungals is also an increasing problem
in C. neoformans and A. fumigatus infections (450). Thus, development of novel treatment
strategies that do not promote resistance is also critical to treating these infections. Since C.
neoformans and A. fumigatus are important pathogens and not closely related to C. albicans,
examining the efficacy of EntV would provide useful insight into the mechanism of action and
could be used as a novel treatment strategy.

What is the role of the disulfide bridge and how is it formed?
Recall that EntV contains two cysteines that form a putative disulfide bond that is
necessary for bactericidal activity and inhibitory activity against C. albicans (Chapter 4) (358).
Until recently disulfide bond formation in Gram-positive bacteria was not well understood and
was not thought be important (381). However, recently thiol-disulfide oxidoreductases (DsbAlike proteins) have been characterized in Gram-positive actinobacteria (382). Furthermore, a
homolog of dsbA has been identified in E. faecalis and disruption of dsbA by transposon
mutagenesis resulted in reduced inhibitory activity suggesting that dsbA is required for
producing active EntV68. However, the role of the disulfide bond formation by DsbA remains to
be fully elucidated. I are currently examining the role of dsbA in producing active EntV68 and
other possible roles in E. faecalis (Armand Brown, Ph.D.). Currently, there are only limited
reports on the dsbA homolog (EF1088) in E. faecalis thus this work will not only add to our
understand of EntV, but the physiology of E. faecalis.

What role if any does SprE play in post-translational processing of sEntV68?
I hypothesized that GelE and/or SprE proteolytically process EntV. However, I did not
determine the role of SprE for EntV68 activity. To address this, we are currently working on
examining the in vitro processing of EntV in deletion mutant of E. faecalis (ΔgelE, ΔsprE,
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ΔgelEΔsprE) compared to WT. EntV will be purified from the supernatant and cell lysates of the
E. faecalis strains and subjected to SDS-PAGE and visualized by Istern blotting polyclonal
antibodies. Our previous attempts to observe in vivo cleavage of EntV did not work because we
was expressing EntV with a C-terminal Hexa-HIS tag expressed from the endogenous
promoter in the mutant strains and WT E. faecalis. However, I was not able to visualize the
EntV-6XHIS by western blot with HIS antibodies. The EntV-6XHIS construct fully
complemented the ΔentV mutant, suggesting EntV is being produced. This along with our in
silico analysis of proteolytic cleavage by the GelE homolog, thermolysin, suggests that the
Hexa-HIS tag is being cleaved in vivo by GelE.

What is the sEntV68 mode of action against C. albicans?
As previously mentioned, I speculate that EntV interacts with the membrane of C.
albicans at low concentration causing minimal perturbation of the membrane that in turn
disrupts biofilm formation and hyphal morphogenesis. This hypothesis also corresponds with
our mutant library screens, where deletion of genes that disrupt the cell wall components or
increase filamentation are less sensitive to E. faecalis supernatant. Thus, it is plausible that
disruption of the cell wall components masks or interferes with EntV targeting the membrane. If
indeed EntV68 is causing membrane stress by leakage of ions then there should be a change in
membrane potential and intracellular ATP, which can be measured and quantified using
fluorescence assays and bioluminescence assays, respectively (382).
Furthermore, treatment of C. albicans with human AMPs LL-37, β-defensin-3 hβD-3, or
Hst-5 causes vacuolar expansion, which is thought to occur as a result of osmotic stress from
membrane permeabilization and cytosolic ion leakage (280, 451). The vacuole can be
visualized by staining with FM4-64 (Invitrogen), a red fluorescent lipophilic stain that
intercalates into the membrane and then is transported to the vacuole, allowing assessment of
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the physical characteristics of the vacuole (302, 452). This could determine if E. faecalis
causes membrane perturbation resulting in an increase in vacuole size.

Are the other class IIIb bacteriocins active against C. albicans?
Examining the efficacy of the other class IIIb bacteriocins against C. albicans could
provide further insight into the mechanism of action and would also suggest that the
interactions observed between E. faecalis and C. albicans are more widespread, which has
ecological implications. Furthermore, understanding the structure differences and possible
activity differences could contribute to engineering possibilities of EntV68 (51, 453). As
mentioned previously, the potency and stability can be improved by enhancing the
physiochemical properties that contribute to the mode of action. If these bacteriocins are active
against C. albicans the construction of chimeric bacteriocins is possible using different portion
of the class IIIb bacteriocins to create hybrids that may have increased activity and broadened
target spectrums (433). This could also provide insight into what portions of the peptides are
necessary for activity increasing our ability to develop EntV-based treatment strategies.

How does C. albicans gene expression change in the presence of E. faecalis?
The EntV mechanism of action is one of the most important questions left to answer.
Changes in C. albicans gene expression in the presence of E. faecalis, E. faecalis supernatant,
and EntV68 can be used to elucidate the mechanism of action. The most comprehensive way to
address this question would be by RNA sequencing, which would tell us the global changes in
gene expression. This assay can be done in C. albicans grown in the in vitro biofilm assay
grown in YNBAS for 24 hours. Previous studies have observed gene expression changes in C.
albicans grown as monoculture and polymicrobial biofilms with different bacteria and growth
conditions (445). While the transcription factor mutant library screen gives some insight into
gene regulation in the presence E. faecalis supernatant only a select number of genes can be
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assessed, which only include non-essential genes and only a small portion of the genes
expressed by C. albicans. RNA sequencing can also provide insight into gene expression in
different infection models that have already been tested (nematode, macrophage, OPC) or new
models to understand the effects of EntV during colonization and systemic infections. Not only
will RNA sequencing provide insight into gene expression of C. albicans, but also gene
expression of E. faecalis.
I also observed attenuation of E. faecalis virulence in the C. elegans infection model,
where survival of the nematode was increased during co-infection with C. albicans and E.
faecalis compared to nematodes infected with E. faecalis only. The E. faecalis mode of
virulence is less striking than that of C. albicans, where hyphal cells invade through the body of
the nematode. Nematodes infected with E. faecalis become impacted with the bacteria and are
unable to expel them and eventually die (LD~10). Preliminary observation demonstrate that
spent media from C. albicans-E. faecalis biofilms inhibits biofilm formation of E. faecalis
(Melissa Cruz). Furthermore, alteration of bacterial gene expression by C. albicans has been
previously reported, such as what is seen in S. aureus and C. albicans biofilms (42, 454, 455).
This project has overall provided valuable insight into the growing knowledge of
polymicrobial interactions. Moreover, I have demonstrated that a bacteriocin produced by E.
faecalis has therapeutic potential against C. albicans in different in vitro and in vivo assays. The
future directions of this study can lead to advancements in treatment of antifungal resistant C.
albicans by exploiting bacterial mediated mechanisms to treat C. albicans infections.
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